Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s5
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4 , and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.

DrugDDI.d201.s5.e0 0 4
drug
Drugs
DrugDDI.d201.s5.e1 24 40
drug
Cytochrome P450 3A4
DrugDDI.d201.s5.e2 87 92
drug
CYP3A4
DrugDDI.d201.s5.e3 152 157
drug
CYP3A4
DrugDDI.d201.s5.e4 163 171
drug
lapatinib

interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e1 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e2 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e0 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e2 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e1 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e2 DrugDDI.d201.s5.e3 false
interaction DrugDDI.d201.s5.e2 DrugDDI.d201.s5.e4 false
interaction DrugDDI.d201.s5.e3 DrugDDI.d201.s5.e4 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s6
Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.

DrugDDI.d201.s6.e0 16 24
drug
lapatinib
DrugDDI.d201.s6.e1 124 129
drug
CYP3A4

interaction DrugDDI.d201.s6.e0 DrugDDI.d201.s6.e1 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s7
Ketoconazole : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.

DrugDDI.d201.s7.e0 0 11
drug
Ketoconazole
DrugDDI.d201.s7.e1 39 50
drug
ketoconazole
DrugDDI.d201.s7.e2 53 58
drug
CYP3A4
DrugDDI.d201.s7.e3 118 126
drug
lapatinib

interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e1 false
interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e2 false
interaction DrugDDI.d201.s7.e0 DrugDDI.d201.s7.e3 false
interaction DrugDDI.d201.s7.e1 DrugDDI.d201.s7.e2 false
interaction DrugDDI.d201.s7.e1 DrugDDI.d201.s7.e3 true
interaction DrugDDI.d201.s7.e2 DrugDDI.d201.s7.e3 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s8
Carbamazepine : In healthy subjects receiving the CYP3A4 inducer, carbamazepine , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.

DrugDDI.d201.s8.e0 0 12
drug
Carbamazepine
DrugDDI.d201.s8.e1 43 48
drug
CYP3A4
DrugDDI.d201.s8.e2 57 69
drug
carbamazepine
DrugDDI.d201.s8.e3 147 155
drug
lapatinib

interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e1 false
interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e2 false
interaction DrugDDI.d201.s8.e0 DrugDDI.d201.s8.e3 false
interaction DrugDDI.d201.s8.e1 DrugDDI.d201.s8.e2 false
interaction DrugDDI.d201.s8.e1 DrugDDI.d201.s8.e3 false
interaction DrugDDI.d201.s8.e2 DrugDDI.d201.s8.e3 true

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s9
Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1 ).

DrugDDI.d201.s9.e0 0 4
drug
Drugs
DrugDDI.d201.s9.e1 36 44
drug
Lapatinib
DrugDDI.d201.s9.e2 68 78
drug
transporter
DrugDDI.d201.s9.e3 98 102
drug
ABCB1

interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e1 false
interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e2 false
interaction DrugDDI.d201.s9.e0 DrugDDI.d201.s9.e3 false
interaction DrugDDI.d201.s9.e1 DrugDDI.d201.s9.e2 false
interaction DrugDDI.d201.s9.e1 DrugDDI.d201.s9.e3 false
interaction DrugDDI.d201.s9.e2 DrugDDI.d201.s9.e3 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s10
If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.

DrugDDI.d201.s10.e0 26 30
drug
drugs
DrugDDI.d201.s10.e1 71 79
drug
lapatinib

interaction DrugDDI.d201.s10.e0 DrugDDI.d201.s10.e1 false

Abstract Id: DrugDDI.d201
Sentence Id: DrugDDI.d201.s11
Other Chemotherapy Agents : In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine ).

DrugDDI.d201.s11.e0 68 76
drug
lapatinib
DrugDDI.d201.s11.e1 81 92
drug
capecitabine
DrugDDI.d201.s11.e2 154 164
drug
metabolites
DrugDDI.d201.s11.e3 167 178
drug
capecitabine

interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e1 false
interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e2 false
interaction DrugDDI.d201.s11.e0 DrugDDI.d201.s11.e3 false
interaction DrugDDI.d201.s11.e1 DrugDDI.d201.s11.e2 false
interaction DrugDDI.d201.s11.e1 DrugDDI.d201.s11.e3 false
interaction DrugDDI.d201.s11.e2 DrugDDI.d201.s11.e3 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s0
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .

DrugDDI.d581.s0.e0 0 13
drug
Cholestyramine
DrugDDI.d581.s0.e1 17 24
drug
Charcoal
DrugDDI.d581.s0.e2 41 54
drug
cholestyramine
DrugDDI.d581.s0.e3 57 73
drug
activated charcoal
DrugDDI.d581.s0.e4 161 176
drug
active metabolite
DrugDDI.d581.s0.e5 179 189
drug
leflunomide

interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e1 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e2 true
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e0 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e2 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e1 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e3 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e2 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e3 DrugDDI.d581.s0.e4 false
interaction DrugDDI.d581.s0.e3 DrugDDI.d581.s0.e5 false
interaction DrugDDI.d581.s0.e4 DrugDDI.d581.s0.e5 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s1
Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.

DrugDDI.d581.s1.e0 11 15
drug
Drugs
DrugDDI.d581.s1.e1 48 58
drug
leflunomide

interaction DrugDDI.d581.s1.e0 DrugDDI.d581.s1.e1 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s2
This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.

DrugDDI.d581.s2.e0 28 38
drug
leflunomide
DrugDDI.d581.s2.e1 64 68
drug
drugs

interaction DrugDDI.d581.s2.e0 DrugDDI.d581.s2.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s3
In a small (n=30) combination study of ARAVA with methotrexate , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.

DrugDDI.d581.s3.e0 32 36
drug
ARAVA
DrugDDI.d581.s3.e1 41 52
drug
methotrexate
DrugDDI.d581.s3.e2 76 87
drug
liver enzymes

interaction DrugDDI.d581.s3.e0 DrugDDI.d581.s3.e1 true
interaction DrugDDI.d581.s3.e0 DrugDDI.d581.s3.e2 false
interaction DrugDDI.d581.s3.e1 DrugDDI.d581.s3.e2 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s4
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

DrugDDI.d581.s4.e0 45 49
drug
drugs
DrugDDI.d581.s4.e1 76 86
drug
leflunomide

interaction DrugDDI.d581.s4.e0 DrugDDI.d581.s4.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s6
All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

DrugDDI.d581.s6.e0 46 50
drug
drugs
DrugDDI.d581.s6.e1 77 87
drug
leflunomide

interaction DrugDDI.d581.s6.e0 DrugDDI.d581.s6.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s7
Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).

DrugDDI.d581.s7.e0 13 15
drug
met



Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s9
NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.

DrugDDI.d581.s9.e0 0 5
drug
NSAIDs
DrugDDI.d581.s9.e1 86 95
drug
diclofenac
DrugDDI.d581.s9.e2 99 107
drug
ibuprofen

interaction DrugDDI.d581.s9.e0 DrugDDI.d581.s9.e1 false
interaction DrugDDI.d581.s9.e0 DrugDDI.d581.s9.e2 false
interaction DrugDDI.d581.s9.e1 DrugDDI.d581.s9.e2 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s11
however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.

DrugDDI.d581.s11.e0 41 46
drug
NSAIDs



Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s12
Tolbutamide : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.

DrugDDI.d581.s12.e0 0 10
drug
Tolbutamide
DrugDDI.d581.s12.e1 91 101
drug
tolbutamide

interaction DrugDDI.d581.s12.e0 DrugDDI.d581.s12.e1 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s14
Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.

DrugDDI.d581.s14.e0 0 7
drug
Rifampin
DrugDDI.d581.s14.e1 57 61
drug
ARAVA
DrugDDI.d581.s14.e2 96 103
drug
rifampin
DrugDDI.d581.s14.e3 153 157
drug
ARAVA

interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e1 false
interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e2 false
interaction DrugDDI.d581.s14.e0 DrugDDI.d581.s14.e3 false
interaction DrugDDI.d581.s14.e1 DrugDDI.d581.s14.e2 true
interaction DrugDDI.d581.s14.e1 DrugDDI.d581.s14.e3 false
interaction DrugDDI.d581.s14.e2 DrugDDI.d581.s14.e3 false

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s15
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin .

DrugDDI.d581.s15.e0 24 28
drug
ARAVA
DrugDDI.d581.s15.e1 123 127
drug
ARAVA
DrugDDI.d581.s15.e2 131 138
drug
rifampin

interaction DrugDDI.d581.s15.e0 DrugDDI.d581.s15.e1 false
interaction DrugDDI.d581.s15.e0 DrugDDI.d581.s15.e2 false
interaction DrugDDI.d581.s15.e1 DrugDDI.d581.s15.e2 true

Abstract Id: DrugDDI.d581
Sentence Id: DrugDDI.d581.s16
Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.

DrugDDI.d581.s16.e0 0 7
drug
Warfarin
DrugDDI.d581.s16.e1 54 58
drug
ARAVA
DrugDDI.d581.s16.e2 62 69
drug
warfarin

interaction DrugDDI.d581.s16.e0 DrugDDI.d581.s16.e1 false
interaction DrugDDI.d581.s16.e0 DrugDDI.d581.s16.e2 false
interaction DrugDDI.d581.s16.e1 DrugDDI.d581.s16.e2 true

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s0
Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.

DrugDDI.d379.s0.e0 30 39
drug
cimetidine
DrugDDI.d379.s0.e1 43 50
drug
warfarin
DrugDDI.d379.s0.e2 85 90
drug
Femara
DrugDDI.d379.s0.e3 100 104
drug
drugs

interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e1 false
interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e2 false
interaction DrugDDI.d379.s0.e0 DrugDDI.d379.s0.e3 false
interaction DrugDDI.d379.s0.e1 DrugDDI.d379.s0.e2 false
interaction DrugDDI.d379.s0.e1 DrugDDI.d379.s0.e3 false
interaction DrugDDI.d379.s0.e2 DrugDDI.d379.s0.e3 false

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s1
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.

DrugDDI.d379.s1.e0 43 48
drug
Femara
DrugDDI.d379.s1.e1 52 64
drug
tamoxifen 20 mg
DrugDDI.d379.s1.e2 92 100
drug
letrozole

interaction DrugDDI.d379.s1.e0 DrugDDI.d379.s1.e1 true
interaction DrugDDI.d379.s1.e0 DrugDDI.d379.s1.e2 false
interaction DrugDDI.d379.s1.e1 DrugDDI.d379.s1.e2 false

Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s2
There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

DrugDDI.d379.s2.e0 43 48
drug
Femara



Abstract Id: DrugDDI.d379
Sentence Id: DrugDDI.d379.s3
Drug /Laboratory Test-Interactions None observed.

DrugDDI.d379.s3.e0 0 3
drug
Drug



Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s0
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients.

DrugDDI.d341.s0.e0 0 8
drug
Folic acid
DrugDDI.d341.s0.e1 39 51
drug
antiepileptic
DrugDDI.d341.s0.e2 60 72
drug
phenobarbital
DrugDDI.d341.s0.e3 74 82
drug
phenytoin
DrugDDI.d341.s0.e4 86 94
drug
primidone
DrugDDI.d341.s0.e5 142 150
drug
pediatric

interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e1 false
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e2 true
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e4 true
interaction DrugDDI.d341.s0.e0 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e2 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e1 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e3 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e2 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e3 DrugDDI.d341.s0.e4 false
interaction DrugDDI.d341.s0.e3 DrugDDI.d341.s0.e5 false
interaction DrugDDI.d341.s0.e4 DrugDDI.d341.s0.e5 false

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s1
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.

DrugDDI.d341.s1.e0 86 95
drug
leucovorin
DrugDDI.d341.s1.e1 200 211
drug
methotrexate

interaction DrugDDI.d341.s1.e0 DrugDDI.d341.s1.e1 false

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s2
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate .

DrugDDI.d341.s2.e0 19 28
drug
leucovorin
DrugDDI.d341.s2.e1 76 87
drug
methotrexate

interaction DrugDDI.d341.s2.e0 DrugDDI.d341.s2.e1 true

Abstract Id: DrugDDI.d341
Sentence Id: DrugDDI.d341.s3
Leucovorin may enhance the toxicity of 5- fluorouracil .

DrugDDI.d341.s3.e0 0 9
drug
Leucovorin
DrugDDI.d341.s3.e1 35 46
drug
fluorouracil

interaction DrugDDI.d341.s3.e0 DrugDDI.d341.s3.e1 true

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s0
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.

DrugDDI.d484.s0.e0 8 14
drug
BETAGAN
DrugDDI.d484.s0.e1 99 105
drug
BETAGAN
DrugDDI.d484.s0.e2 109 119
drug
epinephrine

interaction DrugDDI.d484.s0.e0 DrugDDI.d484.s0.e1 false
interaction DrugDDI.d484.s0.e0 DrugDDI.d484.s0.e2 false
interaction DrugDDI.d484.s0.e1 DrugDDI.d484.s0.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s1
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.

DrugDDI.d484.s1.e0 46 57
drug
beta-blocker
DrugDDI.d484.s1.e1 114 118
drug
drugs
DrugDDI.d484.s1.e2 125 133
drug
reserpine

interaction DrugDDI.d484.s1.e0 DrugDDI.d484.s1.e1 true
interaction DrugDDI.d484.s1.e0 DrugDDI.d484.s1.e2 false
interaction DrugDDI.d484.s1.e1 DrugDDI.d484.s1.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s2
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonist s should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.

DrugDDI.d484.s2.e0 17 45
drug
beta-adrenergic blocking agents
DrugDDI.d484.s2.e1 78 94
drug
calcium antagonist
DrugDDI.d484.s2.new.DISO.e2 124 161
DISO
atrioventricular conduction disturbances
DrugDDI.d484.s2.new.DISO.e3 167 184
DISO
ventricular failure

interaction DrugDDI.d484.s2.e0 DrugDDI.d484.s2.e1 true

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s4
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonist s may have additive effects on prolonging atrioventricular conduction time.

DrugDDI.d484.s4.e0 19 47
drug
beta-adrenergic blocking agents
DrugDDI.d484.s4.e1 52 60
drug
digitalis
DrugDDI.d484.s4.e2 64 80
drug
calcium antagonist

interaction DrugDDI.d484.s4.e0 DrugDDI.d484.s4.e1 true
interaction DrugDDI.d484.s4.e0 DrugDDI.d484.s4.e2 false
interaction DrugDDI.d484.s4.e1 DrugDDI.d484.s4.e2 false

Abstract Id: DrugDDI.d484
Sentence Id: DrugDDI.d484.s5
Phenothiazine -related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other@s metabolism.

DrugDDI.d484.s5.e0 0 12
drug
Phenothiazine
DrugDDI.d484.s5.e1 33 61
drug
beta-adrenergic blocking agents

interaction DrugDDI.d484.s5.e0 DrugDDI.d484.s5.e1 true

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s0
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , cimetidine and phenobarbital .

DrugDDI.d112.s0.e0 86 104
drug
hydrochlorothiazide
DrugDDI.d112.s0.e1 106 112
drug
digoxin
DrugDDI.d112.s0.e2 114 121
drug
warfarin
DrugDDI.d112.s0.e3 123 132
drug
cimetidine
DrugDDI.d112.s0.e4 136 148
drug
phenobarbital

interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e1 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e2 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e0 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e2 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e1 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e2 DrugDDI.d112.s0.e3 false
interaction DrugDDI.d112.s0.e2 DrugDDI.d112.s0.e4 false
interaction DrugDDI.d112.s0.e3 DrugDDI.d112.s0.e4 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s1
Rifampin , an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite .

DrugDDI.d112.s1.e0 0 7
drug
Rifampin
DrugDDI.d112.s1.e1 63 70
drug
losartan
DrugDDI.d112.s1.e2 77 92
drug
active metabolite

interaction DrugDDI.d112.s1.e0 DrugDDI.d112.s1.e1 true
interaction DrugDDI.d112.s1.e0 DrugDDI.d112.s1.e2 false
interaction DrugDDI.d112.s1.e1 DrugDDI.d112.s1.e2 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s2
In humans, two inhibitors of P450 3A4 have been studied.

DrugDDI.d112.s2.e0 24 30
drug
P450 3A4



Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s3
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration.

DrugDDI.d112.s3.e0 0 11
drug
Ketoconazole
DrugDDI.d112.s3.e1 39 46
drug
losartan
DrugDDI.d112.s3.e2 52 67
drug
active metabolite
DrugDDI.d112.s3.e3 100 107
drug
losartan
DrugDDI.d112.s3.e4 112 123
drug
erythromycin

interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e1 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e2 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e0 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e2 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e1 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e2 DrugDDI.d112.s3.e3 false
interaction DrugDDI.d112.s3.e2 DrugDDI.d112.s3.e4 false
interaction DrugDDI.d112.s3.e3 DrugDDI.d112.s3.e4 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s4
Fluconazole , an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.

DrugDDI.d112.s4.e0 0 10
drug
Fluconazole
DrugDDI.d112.s4.e1 25 28
drug
P450
DrugDDI.d112.s4.e2 42 57
drug
active metabolite
DrugDDI.d112.s4.e3 83 90
drug
losartan

interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e1 false
interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e2 true
interaction DrugDDI.d112.s4.e0 DrugDDI.d112.s4.e3 false
interaction DrugDDI.d112.s4.e1 DrugDDI.d112.s4.e2 false
interaction DrugDDI.d112.s4.e1 DrugDDI.d112.s4.e3 false
interaction DrugDDI.d112.s4.e2 DrugDDI.d112.s4.e3 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s5
The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.

DrugDDI.d112.s5.e0 48 55
drug
losartan
DrugDDI.d112.s5.e1 71 74
drug
P450

interaction DrugDDI.d112.s5.e0 DrugDDI.d112.s5.e1 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s6
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9 .

DrugDDI.d112.s6.e0 26 33
drug
losartan
DrugDDI.d112.s6.e1 36 51
drug
active metabolite
DrugDDI.d112.s6.e2 93 109
drug
cytochrome P450 2C9

interaction DrugDDI.d112.s6.e0 DrugDDI.d112.s6.e1 false
interaction DrugDDI.d112.s6.e0 DrugDDI.d112.s6.e2 false
interaction DrugDDI.d112.s6.e1 DrugDDI.d112.s6.e2 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s7
These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4 .

DrugDDI.d112.s7.e0 35 42
drug
losartan
DrugDDI.d112.s7.e1 48 63
drug
active metabolite
DrugDDI.d112.s7.e2 85 88
drug
P450
DrugDDI.d112.s7.e3 98 104
drug
P450 3A4

interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e1 false
interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e2 true
interaction DrugDDI.d112.s7.e0 DrugDDI.d112.s7.e3 false
interaction DrugDDI.d112.s7.e1 DrugDDI.d112.s7.e2 false
interaction DrugDDI.d112.s7.e1 DrugDDI.d112.s7.e3 false
interaction DrugDDI.d112.s7.e2 DrugDDI.d112.s7.e3 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s8
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone , triamterene , amiloride ), potassium supplement s, or salt substitutes containing potassium may lead to increases in serum potassium.

DrugDDI.d112.s8.e0 11 15
drug
drugs
DrugDDI.d112.s8.e1 25 37
drug
angiotensin II
DrugDDI.d112.s8.e2 67 92
drug
potassium-sparing diuretics
DrugDDI.d112.s8.e3 99 112
drug
spironolactone
DrugDDI.d112.s8.e4 114 124
drug
triamterene
DrugDDI.d112.s8.e5 126 134
drug
amiloride
DrugDDI.d112.s8.e6 137 155
drug
potassium supplement
DrugDDI.d112.s8.e7 160 163
drug
salt
DrugDDI.d112.s8.e8 185 193
drug
potassium

interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e1 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e2 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e0 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e2 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e1 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e3 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e6 true
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e2 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e4 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e7 true
interaction DrugDDI.d112.s8.e3 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e5 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e6 true
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e4 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e6 false
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e7 true
interaction DrugDDI.d112.s8.e5 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e6 DrugDDI.d112.s8.e7 false
interaction DrugDDI.d112.s8.e6 DrugDDI.d112.s8.e8 false
interaction DrugDDI.d112.s8.e7 DrugDDI.d112.s8.e8 false

Abstract Id: DrugDDI.d112
Sentence Id: DrugDDI.d112.s9
As with other antihypertensive agents , the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin .

DrugDDI.d112.s9.e0 11 32
drug
antihypertensive agents
DrugDDI.d112.s9.e1 37 52
drug
antihypertensive
DrugDDI.d112.s9.e2 61 68
drug
losartan
DrugDDI.d112.s9.e3 86 119
drug
non-steroidal anti-inflammatory drug

interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e1 false
interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e2 false
interaction DrugDDI.d112.s9.e0 DrugDDI.d112.s9.e3 false
interaction DrugDDI.d112.s9.e1 DrugDDI.d112.s9.e2 false
interaction DrugDDI.d112.s9.e1 DrugDDI.d112.s9.e3 false
interaction DrugDDI.d112.s9.e2 DrugDDI.d112.s9.e3 true

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s0
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics .

DrugDDI.d464.s0.e0 41 45
drug
drugs
DrugDDI.d464.s0.e1 61 97
drug
beta-adrenergic receptor blocking agents
DrugDDI.d464.s0.e2 99 109
drug
Anesthetics
DrugDDI.d464.s0.e3 156 173
drug
general anesthetics

interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e1 true
interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e2 false
interaction DrugDDI.d464.s0.e0 DrugDDI.d464.s0.e3 false
interaction DrugDDI.d464.s0.e1 DrugDDI.d464.s0.e2 true
interaction DrugDDI.d464.s0.e1 DrugDDI.d464.s0.e3 false
interaction DrugDDI.d464.s0.e2 DrugDDI.d464.s0.e3 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s1
Antidiabetic drugs (oral agents and insulin ): hypoglycemia or hyperglycemia; .

DrugDDI.d464.s1.e0 0 16
drug
Antidiabetic drugs
DrugDDI.d464.s1.e1 31 37
drug
insulin
DrugDDI.d464.s1.new.DISO.e2 40 51
DISO
hypoglycemia
DrugDDI.d464.s1.new.DISO.e3 54 66
DISO
hyperglycemia

interaction DrugDDI.d464.s1.e0 DrugDDI.d464.s1.e1 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s2
adjust dosage of antidiabetic drug accordingly.

DrugDDI.d464.s2.e0 14 29
drug
antidiabetic drug



Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s3
Catecholamine-depleting drugs (e.g., reserpine ): additive effect; .

DrugDDI.d464.s3.e0 23 27
drug
drugs
DrugDDI.d464.s3.e1 34 42
drug
reserpine

interaction DrugDDI.d464.s3.e0 DrugDDI.d464.s3.e1 false

Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s5
Response to Treatment for Anaphylactic Reaction: While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

DrugDDI.d464.s5.e0 54 66
drug
beta-blockers



Abstract Id: DrugDDI.d464
Sentence Id: DrugDDI.d464.s6
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

DrugDDI.d464.s6.e0 46 56
drug
epinephrine



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s0
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.

DrugDDI.d485.s0.e0 22 33
drug
theophylline
DrugDDI.d485.s0.e1 65 73
drug
quinolone

interaction DrugDDI.d485.s0.e0 DrugDDI.d485.s0.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s1
There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .

DrugDDI.d485.s1.e0 22 33
drug
theophylline
DrugDDI.d485.s1.e1 87 96
drug
quinolones
DrugDDI.d485.s1.e2 100 111
drug
theophylline

interaction DrugDDI.d485.s1.e0 DrugDDI.d485.s1.e1 false
interaction DrugDDI.d485.s1.e0 DrugDDI.d485.s1.e2 false
interaction DrugDDI.d485.s1.e1 DrugDDI.d485.s1.e2 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.

DrugDDI.d485.s2.e0 22 33
drug
theophylline



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s3
Quinolones have been shown to interfere with the metabolism of caffeine .

DrugDDI.d485.s3.e0 0 9
drug
Quinolones
DrugDDI.d485.s3.e1 53 60
drug
caffeine

interaction DrugDDI.d485.s3.e0 DrugDDI.d485.s3.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s4
This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.

DrugDDI.d485.s4.e0 31 38
drug
caffeine



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s5
Quinolones , including nalidixic acid , may enhance the effects of the oral anticoagulant warfarin or its derivatives .

DrugDDI.d485.s5.e0 0 9
drug
Quinolones
DrugDDI.d485.s5.e1 20 32
drug
nalidixic acid
DrugDDI.d485.s5.e2 59 83
drug
oral anticoagulant warfarin
DrugDDI.d485.s5.e3 89 99
drug
derivatives

interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e1 false
interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e2 true
interaction DrugDDI.d485.s5.e0 DrugDDI.d485.s5.e3 false
interaction DrugDDI.d485.s5.e1 DrugDDI.d485.s5.e2 false
interaction DrugDDI.d485.s5.e1 DrugDDI.d485.s5.e3 true
interaction DrugDDI.d485.s5.e2 DrugDDI.d485.s5.e3 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s7
Nitrofurantoin interferes with the therapeutic action of nalidixic acid .

DrugDDI.d485.s7.e0 0 13
drug
Nitrofurantoin
DrugDDI.d485.s7.e1 50 62
drug
nalidixic acid

interaction DrugDDI.d485.s7.e0 DrugDDI.d485.s7.e1 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s8
Antacids containing magnesium , aluminum, or calcium ; .

DrugDDI.d485.s8.e0 0 7
drug
Antacids
DrugDDI.d485.s8.e1 18 26
drug
magnesium
DrugDDI.d485.s8.e2 39 45
drug
calcium

interaction DrugDDI.d485.s8.e0 DrugDDI.d485.s8.e1 false
interaction DrugDDI.d485.s8.e0 DrugDDI.d485.s8.e2 false
interaction DrugDDI.d485.s8.e1 DrugDDI.d485.s8.e2 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s9
sucralfate or divalent or trivalent cations such as iron ; .

DrugDDI.d485.s9.e0 0 9
drug
sucralfate
DrugDDI.d485.s9.e1 31 37
drug
cations
DrugDDI.d485.s9.e2 44 47
drug
iron

interaction DrugDDI.d485.s9.e0 DrugDDI.d485.s9.e1 false
interaction DrugDDI.d485.s9.e0 DrugDDI.d485.s9.e2 false
interaction DrugDDI.d485.s9.e1 DrugDDI.d485.s9.e2 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s10
multivitamins containing zinc ; .

DrugDDI.d485.s10.e0 0 12
drug
multivitamins
DrugDDI.d485.s10.e1 23 26
drug
zinc

interaction DrugDDI.d485.s10.e0 DrugDDI.d485.s10.e1 false

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s11
and Videx@, ( Didanosine ), chewable/ buffer ed tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired.

DrugDDI.d485.s11.e0 11 20
drug
Didanosine
DrugDDI.d485.s11.e1 32 37
drug
buffer
DrugDDI.d485.s11.e2 52 60
drug
pediatric
DrugDDI.d485.s11.e3 126 135
drug
quinolones

interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e1 false
interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e2 false
interaction DrugDDI.d485.s11.e0 DrugDDI.d485.s11.e3 true
interaction DrugDDI.d485.s11.e1 DrugDDI.d485.s11.e2 false
interaction DrugDDI.d485.s11.e1 DrugDDI.d485.s11.e3 true
interaction DrugDDI.d485.s11.e2 DrugDDI.d485.s11.e3 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s12
These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.

DrugDDI.d485.s12.e0 85 97
drug
nalidixic acid



Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s13
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .

DrugDDI.d485.s13.e0 21 32
drug
cyclosporine
DrugDDI.d485.s13.e1 76 85
drug
quinolones
DrugDDI.d485.s13.e2 89 100
drug
cyclosporine

interaction DrugDDI.d485.s13.e0 DrugDDI.d485.s13.e1 false
interaction DrugDDI.d485.s13.e0 DrugDDI.d485.s13.e2 false
interaction DrugDDI.d485.s13.e1 DrugDDI.d485.s13.e2 true

Abstract Id: DrugDDI.d485
Sentence Id: DrugDDI.d485.s14
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.

DrugDDI.d485.s14.e0 10 21
drug
cyclosporine
DrugDDI.d485.s14.e1 64 75
drug
cyclosporine
DrugDDI.d485.s14.e2 106 110
drug
drugs

interaction DrugDDI.d485.s14.e0 DrugDDI.d485.s14.e1 false
interaction DrugDDI.d485.s14.e0 DrugDDI.d485.s14.e2 false
interaction DrugDDI.d485.s14.e1 DrugDDI.d485.s14.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s0
In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).

DrugDDI.d249.s0.e0 40 46
drug
Starlix
DrugDDI.d249.s0.e1 78 91
drug
cytochrome P450
DrugDDI.d249.s0.e2 128 133
drug
CYP3A4

interaction DrugDDI.d249.s0.e0 DrugDDI.d249.s0.e1 true
interaction DrugDDI.d249.s0.e0 DrugDDI.d249.s0.e2 false
interaction DrugDDI.d249.s0.e1 DrugDDI.d249.s0.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s1
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide .

DrugDDI.d249.s1.e0 0 6
drug
Starlix
DrugDDI.d249.s1.e1 33 47
drug
CYP2C9 isoenzyme
DrugDDI.d249.s1.e2 108 118
drug
tolbutamide

interaction DrugDDI.d249.s1.e0 DrugDDI.d249.s1.e1 true
interaction DrugDDI.d249.s1.e0 DrugDDI.d249.s1.e2 false
interaction DrugDDI.d249.s1.e1 DrugDDI.d249.s1.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s2
Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.

DrugDDI.d249.s2.e0 12 17
drug
CYP3A4



Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s3
Glyburide : In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.

DrugDDI.d249.s3.e0 0 8
drug
Glyburide
DrugDDI.d249.s3.e1 98 104
drug
Starlix
DrugDDI.d249.s3.e2 154 162
drug
glyburide

interaction DrugDDI.d249.s3.e0 DrugDDI.d249.s3.e1 false
interaction DrugDDI.d249.s3.e0 DrugDDI.d249.s3.e2 false
interaction DrugDDI.d249.s3.e1 DrugDDI.d249.s3.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s5
Metformin : When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.

DrugDDI.d249.s5.e0 0 8
drug
Metformin
DrugDDI.d249.s5.e1 14 20
drug
Starlix
DrugDDI.d249.s5.e2 84 97
drug
metformin 500 mg
DrugDDI.d249.s5.new.DISO.e3 127 139
DISO
Type 2 diabetes

interaction DrugDDI.d249.s5.e0 DrugDDI.d249.s5.e1 false
interaction DrugDDI.d249.s5.e0 DrugDDI.d249.s5.e2 false
interaction DrugDDI.d249.s5.e1 DrugDDI.d249.s5.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s6
Digoxin : When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.

DrugDDI.d249.s6.e0 0 6
drug
Digoxin
DrugDDI.d249.s6.e1 12 18
drug
Starlix
DrugDDI.d249.s6.e2 84 90
drug
digoxin

interaction DrugDDI.d249.s6.e0 DrugDDI.d249.s6.e1 false
interaction DrugDDI.d249.s6.e0 DrugDDI.d249.s6.e2 false
interaction DrugDDI.d249.s6.e1 DrugDDI.d249.s6.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s7
Warfarin : When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.

DrugDDI.d249.s7.e0 0 7
drug
Warfarin
DrugDDI.d249.s7.e1 44 50
drug
Starlix
DrugDDI.d249.s7.e2 123 130
drug
warfarin

interaction DrugDDI.d249.s7.e0 DrugDDI.d249.s7.e1 false
interaction DrugDDI.d249.s7.e0 DrugDDI.d249.s7.e2 false
interaction DrugDDI.d249.s7.e1 DrugDDI.d249.s7.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s9
Diclofenac : Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.

DrugDDI.d249.s9.e0 0 9
drug
Diclofenac
DrugDDI.d249.s9.e1 49 55
drug
Starlix
DrugDDI.d249.s9.e2 96 105
drug
diclofenac

interaction DrugDDI.d249.s9.e0 DrugDDI.d249.s9.e1 false
interaction DrugDDI.d249.s9.e0 DrugDDI.d249.s9.e2 false
interaction DrugDDI.d249.s9.e1 DrugDDI.d249.s9.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s10
Nateglinide is highly bound to plasma proteins (98%), mainly albumin .

DrugDDI.d249.s10.e0 0 10
drug
Nateglinide
DrugDDI.d249.s10.e1 26 39
drug
plasma proteins
DrugDDI.d249.s10.e2 52 58
drug
albumin

interaction DrugDDI.d249.s10.e0 DrugDDI.d249.s10.e1 false
interaction DrugDDI.d249.s10.e0 DrugDDI.d249.s10.e2 false
interaction DrugDDI.d249.s10.e1 DrugDDI.d249.s10.e2 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s11
In vitro displacement studies with highly protein -bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding.

DrugDDI.d249.s11.e0 36 42
drug
protein
DrugDDI.d249.s11.e1 60 69
drug
furosemide
DrugDDI.d249.s11.e2 71 81
drug
propranolol
DrugDDI.d249.s11.e3 83 91
drug
captopril
DrugDDI.d249.s11.e4 93 103
drug
nicardipine
DrugDDI.d249.s11.e5 105 115
drug
pravastatin
DrugDDI.d249.s11.e6 117 125
drug
glyburide
DrugDDI.d249.s11.e7 127 134
drug
warfarin
DrugDDI.d249.s11.e8 136 144
drug
phenytoin
DrugDDI.d249.s11.e9 146 164
drug
acetylsalicylic acid
DrugDDI.d249.s11.e10 166 176
drug
tolbutamide
DrugDDI.d249.s11.e11 181 189
drug
metformin
DrugDDI.d249.s11.e12 220 230
drug
nateglinide

interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e1 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e2 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e0 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e2 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e1 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e3 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e2 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e4 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e3 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e5 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e4 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e6 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e5 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e7 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e6 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e8 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e7 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e9 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e8 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e10 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e9 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e10 DrugDDI.d249.s11.e11 false
interaction DrugDDI.d249.s11.e10 DrugDDI.d249.s11.e12 false
interaction DrugDDI.d249.s11.e11 DrugDDI.d249.s11.e12 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s12
Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic acid , and tolbutamide in vitro .

DrugDDI.d249.s12.e0 10 20
drug
nateglinide
DrugDDI.d249.s12.e1 45 58
drug
protein binding
DrugDDI.d249.s12.e2 61 71
drug
propranolol
DrugDDI.d249.s12.e3 73 81
drug
glyburide
DrugDDI.d249.s12.e4 83 93
drug
nicardipine
DrugDDI.d249.s12.e5 95 102
drug
warfarin
DrugDDI.d249.s12.e6 104 112
drug
phenytoin
DrugDDI.d249.s12.e7 114 132
drug
acetylsalicylic acid
DrugDDI.d249.s12.e8 137 147
drug
tolbutamide

interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e1 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e2 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e0 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e2 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e1 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e3 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e2 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e4 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e3 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e5 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e4 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e6 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e5 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e6 DrugDDI.d249.s12.e7 false
interaction DrugDDI.d249.s12.e6 DrugDDI.d249.s12.e8 false
interaction DrugDDI.d249.s12.e7 DrugDDI.d249.s12.e8 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s14
Certain drugs , including nonsteroidal anti-inflammatory agents ( NSAIDs ), salicylates , monoamine oxidase inhibitors , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs .

DrugDDI.d249.s14.e0 7 11
drug
drugs
DrugDDI.d249.s14.e1 22 56
drug
nonsteroidal anti-inflammatory agents
DrugDDI.d249.s14.e2 58 63
drug
NSAIDs
DrugDDI.d249.s14.e3 66 76
drug
salicylates
DrugDDI.d249.s14.e4 78 103
drug
monoamine oxidase inhibitors
DrugDDI.d249.s14.e5 108 150
drug
non-selective beta-adrenergic-blocking agents
DrugDDI.d249.s14.e6 167 184
drug
hypoglycemic action
DrugDDI.d249.s14.e7 187 193
drug
Starlix
DrugDDI.d249.s14.e8 206 222
drug
antidiabetic drugs

interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e1 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e2 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e0 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e2 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e1 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e3 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e2 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e4 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e3 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e5 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e4 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e6 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e5 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e6 DrugDDI.d249.s14.e7 false
interaction DrugDDI.d249.s14.e6 DrugDDI.d249.s14.e8 false
interaction DrugDDI.d249.s14.e7 DrugDDI.d249.s14.e8 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s15
Certain drugs including thiazides , corticosteroids , thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs .

DrugDDI.d249.s15.e0 7 11
drug
drugs
DrugDDI.d249.s15.e1 21 29
drug
thiazides
DrugDDI.d249.s15.e2 31 45
drug
corticosteroids
DrugDDI.d249.s15.e3 47 53
drug
thyroid
DrugDDI.d249.s15.e4 66 81
drug
sympathomimetics
DrugDDI.d249.s15.e5 94 111
drug
hypoglycemic action
DrugDDI.d249.s15.e6 114 120
drug
Starlix
DrugDDI.d249.s15.e7 133 149
drug
antidiabetic drugs

interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e1 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e2 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e0 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e2 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e1 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e3 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e2 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e4 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e3 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e5 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e4 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e5 DrugDDI.d249.s15.e6 false
interaction DrugDDI.d249.s15.e5 DrugDDI.d249.s15.e7 false
interaction DrugDDI.d249.s15.e6 DrugDDI.d249.s15.e7 false

Abstract Id: DrugDDI.d249
Sentence Id: DrugDDI.d249.s16
When these drugs are administered to or withdrawn from patients receiving Starlix , the patient should be observed closely for changes in glycemic control.

DrugDDI.d249.s16.e0 9 13
drug
drugs
DrugDDI.d249.s16.e1 63 69
drug
Starlix

interaction DrugDDI.d249.s16.e0 DrugDDI.d249.s16.e1 false

Abstract Id: DrugDDI.d312
Sentence Id: DrugDDI.d312.s0
In clinical studies, Tilade has been co-administered with other anti-asthma medications , including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities.

DrugDDI.d312.s0.e0 18 23
drug
Tilade
DrugDDI.d312.s0.e1 55 76
drug
anti-asthma medications
DrugDDI.d312.s0.e2 101 115
drug
bronchodilators
DrugDDI.d312.s0.e3 127 141
drug
corticosteroids

interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e1 false
interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e2 false
interaction DrugDDI.d312.s0.e0 DrugDDI.d312.s0.e3 false
interaction DrugDDI.d312.s0.e1 DrugDDI.d312.s0.e2 false
interaction DrugDDI.d312.s0.e1 DrugDDI.d312.s0.e3 false
interaction DrugDDI.d312.s0.e2 DrugDDI.d312.s0.e3 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s0
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin .

DrugDDI.d336.s0.e0 77 81
drug
drugs
DrugDDI.d336.s0.new.DISO.e2 115 128
DISO
nephrotoxicity
DrugDDI.d336.s0.e1 148 155
drug
neomycin

interaction DrugDDI.d336.s0.e0 DrugDDI.d336.s0.e1 true

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s1
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin@s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate@s neuromuscular blocking effects.

DrugDDI.d336.s1.e0 54 68
drug
aminoglycosides
DrugDDI.d336.s1.e1 72 81
drug
polymyxins
DrugDDI.d336.s1.new.DISO.e3 113 126
DISO
nephrotoxicity
DrugDDI.d336.s1.e2 157 164
drug
neomycin

interaction DrugDDI.d336.s1.e0 DrugDDI.d336.s1.e1 true
interaction DrugDDI.d336.s1.e0 DrugDDI.d336.s1.e2 false
interaction DrugDDI.d336.s1.e1 DrugDDI.d336.s1.e2 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s2
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral vitamin B-12 , methotrexate and 5-fluorouracil .

DrugDDI.d336.s2.e0 0 11
drug
Oral neomycin
DrugDDI.d336.s2.e1 51 61
drug
penicillin V
DrugDDI.d336.s2.e2 63 77
drug
oral vitamin B-12
DrugDDI.d336.s2.e3 79 90
drug
methotrexate
DrugDDI.d336.s2.e4 94 107
drug
5-fluorouracil

interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e1 true
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e2 false
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e3 true
interaction DrugDDI.d336.s2.e0 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e2 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e3 false
interaction DrugDDI.d336.s2.e1 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e2 DrugDDI.d336.s2.e3 false
interaction DrugDDI.d336.s2.e2 DrugDDI.d336.s2.e4 false
interaction DrugDDI.d336.s2.e3 DrugDDI.d336.s2.e4 false

Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s3
The gastrointestinal absorption of digoxin also appears to be inhibited.

DrugDDI.d336.s3.e0 31 37
drug
digoxin



Abstract Id: DrugDDI.d336
Sentence Id: DrugDDI.d336.s5
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.

DrugDDI.d336.s5.e0 0 11
drug
Oral neomycin
DrugDDI.d336.s5.e1 40 47
drug
coumarin
DrugDDI.d336.s5.e2 50 63
drug
anticoagulants

interaction DrugDDI.d336.s5.e0 DrugDDI.d336.s5.e1 true
interaction DrugDDI.d336.s5.e0 DrugDDI.d336.s5.e2 false
interaction DrugDDI.d336.s5.e1 DrugDDI.d336.s5.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s0
Beta-adrenergic Blocking Agents : Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agent s is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

DrugDDI.d266.s0.e0 0 28
drug
Beta-adrenergic Blocking Agents
DrugDDI.d266.s0.e1 128 137
drug
nifedipine
DrugDDI.d266.s0.e2 141 158
drug
beta-blocking agent
DrugDDI.d266.s0.new.DISO.e3 280 301
DISO
congestive heart failure

interaction DrugDDI.d266.s0.e0 DrugDDI.d266.s0.e1 false
interaction DrugDDI.d266.s0.e0 DrugDDI.d266.s0.e2 false
interaction DrugDDI.d266.s0.e1 DrugDDI.d266.s0.e2 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s1
Long Acting Nitrates : Nifedipine may be safely co-administered with nitrates , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

DrugDDI.d266.s1.e0 10 17
drug
Nitrates
DrugDDI.d266.s1.e1 19 28
drug
Nifedipine
DrugDDI.d266.s1.e2 59 66
drug
nitrates

interaction DrugDDI.d266.s1.e0 DrugDDI.d266.s1.e1 false
interaction DrugDDI.d266.s1.e0 DrugDDI.d266.s1.e2 false
interaction DrugDDI.d266.s1.e1 DrugDDI.d266.s1.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s2
Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

DrugDDI.d266.s2.e0 0 8
drug
Digitalis
DrugDDI.d266.s2.e1 141 147
drug
digoxin
DrugDDI.d266.s2.e2 151 160
drug
nifedipine
DrugDDI.d266.s2.e3 246 255
drug
nifedipine

interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e1 false
interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e2 false
interaction DrugDDI.d266.s2.e0 DrugDDI.d266.s2.e3 false
interaction DrugDDI.d266.s2.e1 DrugDDI.d266.s2.e2 true
interaction DrugDDI.d266.s2.e1 DrugDDI.d266.s2.e3 false
interaction DrugDDI.d266.s2.e2 DrugDDI.d266.s2.e3 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s3
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.

DrugDDI.d266.s3.e0 39 48
drug
nifedipine
DrugDDI.d266.s3.e1 53 59
drug
digoxin

interaction DrugDDI.d266.s3.e0 DrugDDI.d266.s3.e1 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s7
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

DrugDDI.d266.s7.e0 153 162
drug
nifedipine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s8
Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).

DrugDDI.d266.s8.e0 0 8
drug
Quinidine
DrugDDI.d266.s8.e1 81 89
drug
quinidine
DrugDDI.d266.s8.e2 93 102
drug
nifedipine
DrugDDI.d266.s8.e3 131 139
drug
quinidine

interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e1 false
interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e2 false
interaction DrugDDI.d266.s8.e0 DrugDDI.d266.s8.e3 false
interaction DrugDDI.d266.s8.e1 DrugDDI.d266.s8.e2 true
interaction DrugDDI.d266.s8.e1 DrugDDI.d266.s8.e3 false
interaction DrugDDI.d266.s8.e2 DrugDDI.d266.s8.e3 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s9
Coumarin Anticoagulant s: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulant s to whom nifedipine was administered.

DrugDDI.d266.s9.e0 0 20
drug
Coumarin Anticoagulant
DrugDDI.d266.s9.e1 89 109
drug
coumarin anticoagulant
DrugDDI.d266.s9.e2 117 126
drug
nifedipine

interaction DrugDDI.d266.s9.e0 DrugDDI.d266.s9.e1 false
interaction DrugDDI.d266.s9.e0 DrugDDI.d266.s9.e2 false
interaction DrugDDI.d266.s9.e1 DrugDDI.d266.s9.e2 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s10
However, the relationship to nifedipine therapy is uncertain.

DrugDDI.d266.s10.e0 25 34
drug
nifedipine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s11
Cimetidine : A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.

DrugDDI.d266.s11.e0 0 9
drug
Cimetidine
DrugDDI.d266.s11.e1 71 80
drug
nifedipine
DrugDDI.d266.s11.e2 145 154
drug
cimetidine
DrugDDI.d266.s11.e3 172 181
drug
nifedipine

interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e1 false
interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e2 false
interaction DrugDDI.d266.s11.e0 DrugDDI.d266.s11.e3 false
interaction DrugDDI.d266.s11.e1 DrugDDI.d266.s11.e2 false
interaction DrugDDI.d266.s11.e1 DrugDDI.d266.s11.e3 false
interaction DrugDDI.d266.s11.e2 DrugDDI.d266.s11.e3 true

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s12
Ranitidine produced smaller, non-significant increases.

DrugDDI.d266.s12.e0 0 9
drug
Ranitidine



Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s13
The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450 , the enzyme system probably responsible for the first-pass metabolism of nifedipine .

DrugDDI.d266.s13.e0 44 53
drug
cimetidine
DrugDDI.d266.s13.e1 63 77
drug
cytochrome P-450
DrugDDI.d266.s13.e2 141 150
drug
nifedipine

interaction DrugDDI.d266.s13.e0 DrugDDI.d266.s13.e1 false
interaction DrugDDI.d266.s13.e0 DrugDDI.d266.s13.e2 true
interaction DrugDDI.d266.s13.e1 DrugDDI.d266.s13.e2 false

Abstract Id: DrugDDI.d266
Sentence Id: DrugDDI.d266.s14
If nifedipine therapy is initiated in a patient currently receiving cimetidine , cautious titration is advised.

DrugDDI.d266.s14.e0 2 11
drug
nifedipine
DrugDDI.d266.s14.e1 58 67
drug
cimetidine

interaction DrugDDI.d266.s14.e0 DrugDDI.d266.s14.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s0
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.

DrugDDI.d234.s0.e0 30 40
drug
nisoldipine
DrugDDI.d234.s0.e1 83 97
drug
cimetidine 400 mg

interaction DrugDDI.d234.s0.e0 DrugDDI.d234.s0.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s1
Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).

DrugDDI.d234.s1.e0 0 14
drug
Ranitidine 150 mg
DrugDDI.d234.s1.e1 56 66
drug
nisoldipine

interaction DrugDDI.d234.s1.e0 DrugDDI.d234.s1.e1 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s2
No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.

DrugDDI.d234.s2.e0 32 60
drug
histamine H2 receptor antagonist



Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s3
Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.

DrugDDI.d234.s3.e0 18 26
drug
phenytoin
DrugDDI.d234.s3.e1 35 39
drug
SULAR
DrugDDI.d234.s3.e2 76 86
drug
nisoldipine

interaction DrugDDI.d234.s3.e0 DrugDDI.d234.s3.e1 true
interaction DrugDDI.d234.s3.e0 DrugDDI.d234.s3.e2 false
interaction DrugDDI.d234.s3.e1 DrugDDI.d234.s3.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s4
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.

DrugDDI.d234.s4.e0 18 22
drug
SULAR
DrugDDI.d234.s4.e1 27 35
drug
phenytoin
DrugDDI.d234.s4.e2 46 51
drug
CYP3A4
DrugDDI.d234.s4.e3 88 103
drug
antihypertensive

interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e1 true
interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e2 false
interaction DrugDDI.d234.s4.e0 DrugDDI.d234.s4.e3 false
interaction DrugDDI.d234.s4.e1 DrugDDI.d234.s4.e2 false
interaction DrugDDI.d234.s4.e1 DrugDDI.d234.s4.e3 false
interaction DrugDDI.d234.s4.e2 DrugDDI.d234.s4.e3 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s5
Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant.

DrugDDI.d234.s5.e0 34 44
drug
nisoldipine
DrugDDI.d234.s5.e1 48 60
drug
beta-blockers
DrugDDI.d234.s5.e2 62 69
drug
atenolol
DrugDDI.d234.s5.e3 71 81
drug
propranolol

interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e1 true
interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e2 false
interaction DrugDDI.d234.s5.e0 DrugDDI.d234.s5.e3 true
interaction DrugDDI.d234.s5.e1 DrugDDI.d234.s5.e2 false
interaction DrugDDI.d234.s5.e1 DrugDDI.d234.s5.e3 false
interaction DrugDDI.d234.s5.e2 DrugDDI.d234.s5.e3 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s6
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine .

DrugDDI.d234.s6.e0 0 10
drug
Propranolol
DrugDDI.d234.s6.e1 82 92
drug
nisoldipine

interaction DrugDDI.d234.s6.e0 DrugDDI.d234.s6.e1 true

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s7
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.

DrugDDI.d234.s7.e0 24 28
drug
SULAR
DrugDDI.d234.s7.e1 58 65
drug
atenolol
DrugDDI.d234.s7.e2 89 104
drug
antihypertensive

interaction DrugDDI.d234.s7.e0 DrugDDI.d234.s7.e1 true
interaction DrugDDI.d234.s7.e0 DrugDDI.d234.s7.e2 false
interaction DrugDDI.d234.s7.e1 DrugDDI.d234.s7.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s8
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.

DrugDDI.d234.s8.e0 0 8
drug
Quinidine
DrugDDI.d234.s8.e1 16 18
drug
bid
DrugDDI.d234.s8.e2 53 63
drug
nisoldipine

interaction DrugDDI.d234.s8.e0 DrugDDI.d234.s8.e1 false
interaction DrugDDI.d234.s8.e0 DrugDDI.d234.s8.e2 true
interaction DrugDDI.d234.s8.e1 DrugDDI.d234.s8.e2 false

Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s9
The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.

DrugDDI.d234.s9.e0 51 61
drug
nisoldipine



Abstract Id: DrugDDI.d234
Sentence Id: DrugDDI.d234.s11
No significant interactions were found between nisoldipine and warfarin or digoxin .

DrugDDI.d234.s11.e0 41 51
drug
nisoldipine
DrugDDI.d234.s11.e1 55 62
drug
warfarin
DrugDDI.d234.s11.e2 65 71
drug
digoxin

interaction DrugDDI.d234.s11.e0 DrugDDI.d234.s11.e1 false
interaction DrugDDI.d234.s11.e0 DrugDDI.d234.s11.e2 false
interaction DrugDDI.d234.s11.e1 DrugDDI.d234.s11.e2 false

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s0
Tizoxanide is highly bound to plasma protein ( 99.9%).

DrugDDI.d306.s0.e0 0 9
drug
Tizoxanide
DrugDDI.d306.s0.e1 25 37
drug
plasma protein

interaction DrugDDI.d306.s0.e0 DrugDDI.d306.s0.e1 true

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s1
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin ).

DrugDDI.d306.s1.e0 46 57
drug
nitazoxanide
DrugDDI.d306.s1.e1 180 187
drug
warfarin

interaction DrugDDI.d306.s1.e0 DrugDDI.d306.s1.e1 true

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s2
In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.

DrugDDI.d306.s2.e0 44 53
drug
tizoxanide
DrugDDI.d306.s2.e1 88 101
drug
cytochrome P450

interaction DrugDDI.d306.s2.e0 DrugDDI.d306.s2.e1 false

Abstract Id: DrugDDI.d306
Sentence Id: DrugDDI.d306.s3
Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.

DrugDDI.d306.s3.e0 115 126
drug
nitazoxanide
DrugDDI.d306.s3.e1 148 152
drug
drugs
DrugDDI.d306.s3.e2 188 201
drug
cytochrome P450

interaction DrugDDI.d306.s3.e0 DrugDDI.d306.s3.e1 false
interaction DrugDDI.d306.s3.e0 DrugDDI.d306.s3.e2 false
interaction DrugDDI.d306.s3.e1 DrugDDI.d306.s3.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s0
Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4 /5 with potentially important effects on plasma concentrations of other drugs .

DrugDDI.d20.s0.e0 0 12
drug
Oxcarbazepine
DrugDDI.d20.s0.e1 23 29
drug
CYP2C19
DrugDDI.d20.s0.e2 39 44
drug
CYP3A4
DrugDDI.d20.s0.e3 107 111
drug
drugs

interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e1 false
interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e2 false
interaction DrugDDI.d20.s0.e0 DrugDDI.d20.s0.e3 true
interaction DrugDDI.d20.s0.e1 DrugDDI.d20.s0.e2 false
interaction DrugDDI.d20.s0.e1 DrugDDI.d20.s0.e3 false
interaction DrugDDI.d20.s0.e2 DrugDDI.d20.s0.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s1
In addition, several AED@s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.

DrugDDI.d20.s1.e0 30 43
drug
cytochrome P450
DrugDDI.d20.s1.e1 85 97
drug
oxcarbazepine

interaction DrugDDI.d20.s1.e0 DrugDDI.d20.s1.e1 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s2
Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs .

DrugDDI.d20.s2.e0 0 12
drug
Oxcarbazepine
DrugDDI.d20.s2.e1 86 99
drug
cytochrome P450
DrugDDI.d20.s2.e2 141 145
drug
drugs

interaction DrugDDI.d20.s2.e0 DrugDDI.d20.s2.e1 false
interaction DrugDDI.d20.s2.e0 DrugDDI.d20.s2.e2 false
interaction DrugDDI.d20.s2.e1 DrugDDI.d20.s2.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s3
Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2D6 , CYP2E1 , CYP4A9 and CYP4A11 ) with the exception of CYP2C19 and CYP3A4 /5.

DrugDDI.d20.s3.e0 22 34
drug
oxcarbazepine
DrugDDI.d20.s3.e1 58 87
drug
active 10-monohydroxy metabolite
DrugDDI.d20.s3.e2 154 167
drug
cytochrome P450
DrugDDI.d20.s3.e3 185 190
drug
CYP1A2
DrugDDI.d20.s3.e4 192 197
drug
CYP2A6
DrugDDI.d20.s3.e5 199 204
drug
CYP2C9
DrugDDI.d20.s3.e6 206 211
drug
CYP2D6
DrugDDI.d20.s3.e7 213 218
drug
CYP2E1
DrugDDI.d20.s3.e8 229 235
drug
CYP4A11
DrugDDI.d20.s3.e9 255 261
drug
CYP2C19
DrugDDI.d20.s3.e10 265 270
drug
CYP3A4

interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e1 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e2 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e0 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e2 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e1 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e3 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e2 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e4 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e3 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e5 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e4 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e6 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e5 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e7 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e6 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e8 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e7 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e8 DrugDDI.d20.s3.e9 false
interaction DrugDDI.d20.s3.e8 DrugDDI.d20.s3.e10 false
interaction DrugDDI.d20.s3.e9 DrugDDI.d20.s3.e10 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s4
Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.

DrugDDI.d20.s4.e0 20 22
drug
CYP



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s5
The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.

DrugDDI.d20.s5.e0 15 22
drug
CYP-2C19



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s6
In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.

DrugDDI.d20.s6.e0 11 35
drug
UDP-glucuronyl transferase



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s7
Increases of 22% with MHD and 47% with oxcarbazepine were observed.

DrugDDI.d20.s7.e0 31 43
drug
oxcarbazepine



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s8
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid , lamotrigine ).

DrugDDI.d20.s8.e0 56 80
drug
UDP-glucuronyl transferase
DrugDDI.d20.s8.e1 110 114
drug
drugs
DrugDDI.d20.s8.e2 158 182
drug
UDP-glucuronyl transferase
DrugDDI.d20.s8.e3 189 200
drug
valproic acid
DrugDDI.d20.s8.e4 202 212
drug
lamotrigine

interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e1 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e2 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e0 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e2 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e1 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e2 DrugDDI.d20.s8.e3 false
interaction DrugDDI.d20.s8.e2 DrugDDI.d20.s8.e4 false
interaction DrugDDI.d20.s8.e3 DrugDDI.d20.s8.e4 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s9
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonist s and oral contraceptives , resulting in a lower plasma concentration of these drugs .

DrugDDI.d20.s9.e0 11 23
drug
oxcarbazepine
DrugDDI.d20.s9.e1 50 65
drug
cytochrome P450 3A
DrugDDI.d20.s9.e2 73 78
drug
CYP3A4
DrugDDI.d20.s9.e3 82 87
drug
CYP3A5
DrugDDI.d20.s9.e4 133 149
drug
calcium antagonist
DrugDDI.d20.s9.e5 154 171
drug
oral contraceptives
DrugDDI.d20.s9.e6 216 220
drug
drugs

interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e1 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e2 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e4 true
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e5 true
interaction DrugDDI.d20.s9.e0 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e2 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e1 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e3 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e2 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e4 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e3 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e4 DrugDDI.d20.s9.e5 false
interaction DrugDDI.d20.s9.e4 DrugDDI.d20.s9.e6 false
interaction DrugDDI.d20.s9.e5 DrugDDI.d20.s9.e6 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s10
As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.

DrugDDI.d20.s10.e0 16 29
drug
plasma proteins
DrugDDI.d20.s10.e1 83 87
drug
drugs
DrugDDI.d20.s10.e2 109 115
drug
protein

interaction DrugDDI.d20.s10.e0 DrugDDI.d20.s10.e1 false
interaction DrugDDI.d20.s10.e0 DrugDDI.d20.s10.e2 false
interaction DrugDDI.d20.s10.e1 DrugDDI.d20.s10.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s11
Antiepileptic drugs Potential interactions between Trileptal and other AEDs were assessed in clinical studies.

DrugDDI.d20.s11.e0 0 17
drug
Antiepileptic drugs
DrugDDI.d20.s11.e1 46 54
drug
Trileptal

interaction DrugDDI.d20.s11.e0 DrugDDI.d20.s11.e1 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s12
The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal .

DrugDDI.d20.s12.e0 102 110
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s15
Trileptal dose (mg/day) .

DrugDDI.d20.s15.e0 0 8
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s16
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval) .

DrugDDI.d20.s16.e0 11 19
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s18
Carbamazepine .

DrugDDI.d20.s18.e0 0 12
drug
Carbamazepine



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s22
Phenobarbital .

DrugDDI.d20.s22.e0 0 12
drug
Phenobarbital



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s26
Phenytoin .

DrugDDI.d20.s26.e0 0 8
drug
Phenytoin



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s31
Valproic acid .

DrugDDI.d20.s31.e0 0 11
drug
Valproic acid



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s35
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.

DrugDDI.d20.s35.e0 75 83
drug
Trileptal
DrugDDI.d20.s35.e1 113 121
drug
phenytoin
DrugDDI.d20.s35.e2 145 153
drug
Trileptal

interaction DrugDDI.d20.s35.e0 DrugDDI.d20.s35.e1 false
interaction DrugDDI.d20.s35.e0 DrugDDI.d20.s35.e2 false
interaction DrugDDI.d20.s35.e1 DrugDDI.d20.s35.e2 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s36
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.

DrugDDI.d20.s36.e0 26 34
drug
Trileptal
DrugDDI.d20.s36.e1 100 108
drug
phenytoin

interaction DrugDDI.d20.s36.e0 DrugDDI.d20.s36.e1 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s37
The increase of phenobarbital level, however, is small (15%) when given with Trileptal .

DrugDDI.d20.s37.e0 65 73
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s38
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%).

DrugDDI.d20.s38.e0 16 29
drug
cytochrome P450
DrugDDI.d20.s38.e1 42 54
drug
carbamazepine
DrugDDI.d20.s38.e2 56 64
drug
phenytoin
DrugDDI.d20.s38.e3 68 80
drug
phenobarbital

interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e1 false
interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e2 false
interaction DrugDDI.d20.s38.e0 DrugDDI.d20.s38.e3 false
interaction DrugDDI.d20.s38.e1 DrugDDI.d20.s38.e2 false
interaction DrugDDI.d20.s38.e1 DrugDDI.d20.s38.e3 false
interaction DrugDDI.d20.s38.e2 DrugDDI.d20.s38.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s39
No autoinduction has been observed with Trileptal .

DrugDDI.d20.s39.e0 34 42
drug
Trileptal



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s40
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).

DrugDDI.d20.s40.e0 41 49
drug
Trileptal
DrugDDI.d20.s40.e1 56 72
drug
oral contraceptive
DrugDDI.d20.s40.e2 146 161
drug
ethinylestradiol
DrugDDI.d20.s40.e3 169 182
drug
levonorgestrel

interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e1 true
interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e2 false
interaction DrugDDI.d20.s40.e0 DrugDDI.d20.s40.e3 false
interaction DrugDDI.d20.s40.e1 DrugDDI.d20.s40.e2 false
interaction DrugDDI.d20.s40.e1 DrugDDI.d20.s40.e3 false
interaction DrugDDI.d20.s40.e2 DrugDDI.d20.s40.e3 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s43
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.

DrugDDI.d20.s43.e0 25 33
drug
Trileptal
DrugDDI.d20.s43.e1 46 59
drug
contraceptives
DrugDDI.d20.s43.e2 74 87
drug
contraceptives

interaction DrugDDI.d20.s43.e0 DrugDDI.d20.s43.e1 true
interaction DrugDDI.d20.s43.e0 DrugDDI.d20.s43.e2 false
interaction DrugDDI.d20.s43.e1 DrugDDI.d20.s43.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s44
Studies with other oral or implant contraceptives have not been conducted.

DrugDDI.d20.s44.e0 29 42
drug
contraceptives



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s45
Calcium Antagonist s After repeated co-administration of Trileptal , the AUC of felodipine was lowered by 28% [90% CI: 20-33].

DrugDDI.d20.s45.e0 0 16
drug
Calcium Antagonist
DrugDDI.d20.s45.e1 50 58
drug
Trileptal
DrugDDI.d20.s45.e2 68 77
drug
felodipine

interaction DrugDDI.d20.s45.e0 DrugDDI.d20.s45.e1 false
interaction DrugDDI.d20.s45.e0 DrugDDI.d20.s45.e2 false
interaction DrugDDI.d20.s45.e1 DrugDDI.d20.s45.e2 true

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s46
Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.

DrugDDI.d20.s46.e0 0 8
drug
Verapamil



Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s47
Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.

DrugDDI.d20.s47.e0 21 30
drug
Cimetidine
DrugDDI.d20.s47.e1 32 43
drug
erythromycin
DrugDDI.d20.s47.e2 47 64
drug
dextropropoxyphene

interaction DrugDDI.d20.s47.e0 DrugDDI.d20.s47.e1 false
interaction DrugDDI.d20.s47.e0 DrugDDI.d20.s47.e2 false
interaction DrugDDI.d20.s47.e1 DrugDDI.d20.s47.e2 false

Abstract Id: DrugDDI.d20
Sentence Id: DrugDDI.d20.s48
Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal .

DrugDDI.d20.s48.e0 11 18
drug
warfarin
DrugDDI.d20.s48.e1 80 88
drug
Trileptal

interaction DrugDDI.d20.s48.e0 DrugDDI.d20.s48.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s0
In a Phase : I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin ).

DrugDDI.d480.s0.e0 37 41
drug
TAXOL
DrugDDI.d480.s0.e1 59 67
drug
cisplatin
DrugDDI.d480.s0.e2 143 147
drug
TAXOL
DrugDDI.d480.s0.e3 161 169
drug
cisplatin
DrugDDI.d480.s0.e4 202 206
drug
TAXOL
DrugDDI.d480.s0.e5 213 221
drug
cisplatin

interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e1 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e2 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e0 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e2 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e1 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e3 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e2 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e3 DrugDDI.d480.s0.e4 false
interaction DrugDDI.d480.s0.e3 DrugDDI.d480.s0.e5 false
interaction DrugDDI.d480.s0.e4 DrugDDI.d480.s0.e5 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s1
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .

DrugDDI.d480.s1.e0 59 68
drug
paclitaxel
DrugDDI.d480.s1.e1 100 104
drug
TAXOL
DrugDDI.d480.s1.e2 129 137
drug
cisplatin

interaction DrugDDI.d480.s1.e0 DrugDDI.d480.s1.e1 false
interaction DrugDDI.d480.s1.e0 DrugDDI.d480.s1.e2 false
interaction DrugDDI.d480.s1.e1 DrugDDI.d480.s1.e2 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s2
The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4 .

DrugDDI.d480.s2.e0 15 19
drug
TAXOL
DrugDDI.d480.s2.e1 33 46
drug
cytochrome P450
DrugDDI.d480.s2.e2 67 72
drug
CYP3A4

interaction DrugDDI.d480.s2.e0 DrugDDI.d480.s2.e1 true
interaction DrugDDI.d480.s2.e0 DrugDDI.d480.s2.e2 true
interaction DrugDDI.d480.s2.e1 DrugDDI.d480.s2.e2 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s3
In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4 .

DrugDDI.d480.s3.e0 92 96
drug
TAXOL
DrugDDI.d480.s3.e1 146 159
drug
cytochrome P450
DrugDDI.d480.s3.e2 179 184
drug
CYP3A4

interaction DrugDDI.d480.s3.e0 DrugDDI.d480.s3.e1 true
interaction DrugDDI.d480.s3.e0 DrugDDI.d480.s3.e2 true
interaction DrugDDI.d480.s3.e1 DrugDDI.d480.s3.e2 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s4
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials.

DrugDDI.d480.s4.e0 28 32
drug
TAXOL
DrugDDI.d480.s4.e1 46 51
drug
CYP3A4
DrugDDI.d480.s4.e2 56 73
drug
protease inhibitors
DrugDDI.d480.s4.e3 75 83
drug
ritonavir
DrugDDI.d480.s4.e4 85 94
drug
saquinavir
DrugDDI.d480.s4.e5 96 104
drug
indinavir
DrugDDI.d480.s4.e6 109 118
drug
nelfinavir
DrugDDI.d480.s4.e7 157 162
drug
CYP3A4

interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e1 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e2 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e0 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e2 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e1 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e3 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e2 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e4 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e3 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e5 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e4 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e5 DrugDDI.d480.s4.e6 false
interaction DrugDDI.d480.s4.e5 DrugDDI.d480.s4.e7 false
interaction DrugDDI.d480.s4.e6 DrugDDI.d480.s4.e7 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s5
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.

DrugDDI.d480.s5.e0 47 57
drug
doxorubicin
DrugDDI.d480.s5.e1 65 80
drug
active metabolite
DrugDDI.d480.s5.e2 113 122
drug
paclitaxel
DrugDDI.d480.s5.e3 126 136
drug
doxorubicin

interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e1 false
interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e2 false
interaction DrugDDI.d480.s5.e0 DrugDDI.d480.s5.e3 false
interaction DrugDDI.d480.s5.e1 DrugDDI.d480.s5.e2 false
interaction DrugDDI.d480.s5.e1 DrugDDI.d480.s5.e3 false
interaction DrugDDI.d480.s5.e2 DrugDDI.d480.s5.e3 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s6
Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.

DrugDDI.d480.s6.e0 11 15
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s7
In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL .

DrugDDI.d480.s7.e0 130 134
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s8
Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3.

DrugDDI.d480.s8.e0 51 55
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s9
In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.

DrugDDI.d480.s9.new.DISO.e1 17 27
DISO
neutropenia
DrugDDI.d480.s9.e0 75 79
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s10
For patients with advanced HIV disease and poor-risk AIDS-related Kaposi@s sarcoma, TAXOL , at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.

DrugDDI.d480.s10.e0 23 25
drug
HIV
DrugDDI.d480.s10.new.DISO.e2 65 71
DISO
sarcoma
DrugDDI.d480.s10.e1 73 77
drug
TAXOL

interaction DrugDDI.d480.s10.e0 DrugDDI.d480.s10.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s11
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor@ EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL .

DrugDDI.d480.s11.e0 115 125
drug
cyclosporin
DrugDDI.d480.s11.e1 152 161
drug
teniposide
DrugDDI.d480.s11.e2 208 212
drug
TAXOL

interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e1 false
interaction DrugDDI.d480.s11.e0 DrugDDI.d480.s11.e2 true
interaction DrugDDI.d480.s11.e1 DrugDDI.d480.s11.e2 true

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s12
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen -hydramine and H2 antagonists (such as cimetidine or ranitidine ).

DrugDDI.d480.s12.e0 83 87
drug
TAXOL
DrugDDI.d480.s12.e1 112 126
drug
corticosteroids
DrugDDI.d480.s12.e2 134 146
drug
dexamethasone
DrugDDI.d480.s12.e3 149 154
drug
diphen
DrugDDI.d480.s12.e4 188 197
drug
cimetidine
DrugDDI.d480.s12.e5 200 209
drug
ranitidine

interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e1 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e2 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e0 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e2 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e1 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e3 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e2 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e3 DrugDDI.d480.s12.e4 false
interaction DrugDDI.d480.s12.e3 DrugDDI.d480.s12.e5 false
interaction DrugDDI.d480.s12.e4 DrugDDI.d480.s12.e5 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s14
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators , angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.

DrugDDI.d480.s14.e0 76 90
drug
bronchodilators
DrugDDI.d480.s14.e1 158 162
drug
TAXOL

interaction DrugDDI.d480.s14.e0 DrugDDI.d480.s14.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s15
Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL .

DrugDDI.d480.s15.e0 82 86
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s16
Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL , but generally do not require treatment.

DrugDDI.d480.s16.e0 92 96
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s17
Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.

DrugDDI.d480.s17.e0 12 16
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s18
Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.

DrugDDI.d480.s18.e0 60 64
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s20
Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL .

DrugDDI.d480.s20.new.DISO.e1 37 56
DISO
peripheral neuropathy
DrugDDI.d480.s20.e0 168 172
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s21
TAXOL contains dehydrated alcohol USP , 396 mg/mL; .

DrugDDI.d480.s21.e0 0 4
drug
TAXOL
DrugDDI.d480.s21.e1 13 32
drug
dehydrated alcohol USP

interaction DrugDDI.d480.s21.e0 DrugDDI.d480.s21.e1 false

Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s22
consideration should be given to possible CNS and other effects of alcohol .

DrugDDI.d480.s22.e0 56 62
drug
alcohol



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s23
Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin 2 times ULN.

DrugDDI.d480.s23.e0 52 56
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s24
Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.

DrugDDI.d480.s24.e0 48 52
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s27
Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.

DrugDDI.d480.s27.e0 80 84
drug
TAXOL



Abstract Id: DrugDDI.d480
Sentence Id: DrugDDI.d480.s28
Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.

DrugDDI.d480.s28.new.DISO.e1 35 43
DISO
phlebitis
DrugDDI.d480.s28.new.DISO.e2 45 54
DISO
cellulitis
DrugDDI.d480.s28.new.DISO.e3 83 90
DISO
necrosis
DrugDDI.d480.s28.new.DISO.e4 95 102
DISO
fibrosis
DrugDDI.d480.s28.e0 154 158
drug
TAXOL



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s0
Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .

DrugDDI.d235.s0.e0 0 14
drug
Aminoglycosides
DrugDDI.d235.s0.e1 27 38
drug
piperacillin
DrugDDI.d235.s0.e2 45 58
drug
aminoglycoside
DrugDDI.d235.s0.e3 105 118
drug
aminoglycoside

interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e1 false
interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e2 false
interaction DrugDDI.d235.s0.e0 DrugDDI.d235.s0.e3 false
interaction DrugDDI.d235.s0.e1 DrugDDI.d235.s0.e2 true
interaction DrugDDI.d235.s0.e1 DrugDDI.d235.s0.e3 false
interaction DrugDDI.d235.s0.e2 DrugDDI.d235.s0.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s1
Vecuronium : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium .

DrugDDI.d235.s1.e0 0 9
drug
Vecuronium
DrugDDI.d235.s1.e1 44 55
drug
piperacillin
DrugDDI.d235.s1.e2 118 127
drug
vecuronium

interaction DrugDDI.d235.s1.e0 DrugDDI.d235.s1.e1 false
interaction DrugDDI.d235.s1.e0 DrugDDI.d235.s1.e2 false
interaction DrugDDI.d235.s1.e1 DrugDDI.d235.s1.e2 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s2
Caution is indicated when piperacillin is used perioperatively.

DrugDDI.d235.s2.e0 22 33
drug
piperacillin



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s3
In one controlled clinical study, the ureidopenicillins, including piperacillin , were reported to prolong the action of vecuronium .

DrugDDI.d235.s3.e0 59 70
drug
piperacillin
DrugDDI.d235.s3.e1 104 113
drug
vecuronium

interaction DrugDDI.d235.s3.e0 DrugDDI.d235.s3.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s4
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin .

DrugDDI.d235.s4.e0 93 123
drug
non-depolarizing muscle relaxants
DrugDDI.d235.s4.e1 155 166
drug
piperacillin

interaction DrugDDI.d235.s4.e0 DrugDDI.d235.s4.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s5
Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.

DrugDDI.d235.s5.e0 0 9
drug
Probenecid
DrugDDI.d235.s5.e1 31 40
drug
probenecid
DrugDDI.d235.s5.e2 71 78
drug
PIPRACIL
DrugDDI.d235.s5.e3 99 110
drug
piperacillin

interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e1 false
interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e2 false
interaction DrugDDI.d235.s5.e0 DrugDDI.d235.s5.e3 false
interaction DrugDDI.d235.s5.e1 DrugDDI.d235.s5.e2 true
interaction DrugDDI.d235.s5.e1 DrugDDI.d235.s5.e3 false
interaction DrugDDI.d235.s5.e2 DrugDDI.d235.s5.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s6
Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin , oral anticoagulants , or other drugs that may affect the blood coagulation system or the thrombocyte function.

DrugDDI.d235.s6.e0 0 13
drug
Anticoagulants
DrugDDI.d235.s6.e1 129 135
drug
heparin
DrugDDI.d235.s6.e2 137 154
drug
oral anticoagulants
DrugDDI.d235.s6.e3 163 167
drug
drugs

interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e1 false
interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e2 false
interaction DrugDDI.d235.s6.e0 DrugDDI.d235.s6.e3 false
interaction DrugDDI.d235.s6.e1 DrugDDI.d235.s6.e2 false
interaction DrugDDI.d235.s6.e1 DrugDDI.d235.s6.e3 false
interaction DrugDDI.d235.s6.e2 DrugDDI.d235.s6.e3 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s7
Methotrexate Piperacillin sodium may reduce the excretion of methotrexate .

DrugDDI.d235.s7.e0 0 23
drug
Methotrexate Piperacillin
DrugDDI.d235.s7.e1 53 64
drug
methotrexate

interaction DrugDDI.d235.s7.e0 DrugDDI.d235.s7.e1 true

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s8
Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

DrugDDI.d235.s8.e0 23 34
drug
methotrexate
DrugDDI.d235.s8.new.DISO.e1 69 80
DISO
drug toxicity



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s9
Drug /Laboratory Test Interactions : As with other penicillins , the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper -reduction method.

DrugDDI.d235.s9.e0 0 3
drug
Drug
DrugDDI.d235.s9.e1 38 53
drug
other penicillins
DrugDDI.d235.s9.e2 74 81
drug
PIPRACIL
DrugDDI.d235.s9.e3 119 125
drug
glucose
DrugDDI.d235.s9.e4 142 147
drug
copper

interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e1 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e2 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e0 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e2 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e1 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e2 DrugDDI.d235.s9.e3 false
interaction DrugDDI.d235.s9.e2 DrugDDI.d235.s9.e4 false
interaction DrugDDI.d235.s9.e3 DrugDDI.d235.s9.e4 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s10
It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

DrugDDI.d235.s10.e0 47 60
drug
glucose oxidase



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s11
There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin / tazobactam injection who were subsequently found to be free of Aspergillus infection.

DrugDDI.d235.s11.e0 113 124
drug
piperacillin
DrugDDI.d235.s11.e1 126 135
drug
tazobactam
DrugDDI.d235.s11.new.DISO.e2 179 198
DISO
Aspergillus infection

interaction DrugDDI.d235.s11.e0 DrugDDI.d235.s11.e1 false

Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s12
Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

DrugDDI.d235.s12.e0 34 48
drug
polysaccharides



Abstract Id: DrugDDI.d235
Sentence Id: DrugDDI.d235.s13
Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.

DrugDDI.d235.s13.e0 48 59
drug
piperacillin



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s0
Effect of other drugs on Vardenafil .

DrugDDI.d253.s0.e0 13 17
drug
drugs
DrugDDI.d253.s0.e1 20 29
drug
Vardenafil

interaction DrugDDI.d253.s0.e0 DrugDDI.d253.s0.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s1
In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 ( CYP ) isoforms 3A4/5, and to a lesser degree by CYP2C9 .

DrugDDI.d253.s1.e0 54 63
drug
vardenafil
DrugDDI.d253.s1.e1 88 101
drug
cytochrome P450
DrugDDI.d253.s1.e2 103 105
drug
CYP
DrugDDI.d253.s1.e3 107 114
drug
isoforms
DrugDDI.d253.s1.e4 141 146
drug
CYP2C9

interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e1 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e2 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e0 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e2 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e1 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e2 DrugDDI.d253.s1.e3 false
interaction DrugDDI.d253.s1.e2 DrugDDI.d253.s1.e4 false
interaction DrugDDI.d253.s1.e3 DrugDDI.d253.s1.e4 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s2
Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.

DrugDDI.d253.s2.e0 53 62
drug
vardenafil



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s3
In vivo studies: Cytochrome P450 Inhibitors .

DrugDDI.d253.s3.e0 14 27
drug
Cytochrome P450



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s4
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.

DrugDDI.d253.s4.e0 0 9
drug
Cimetidine
DrugDDI.d253.s4.e1 36 45
drug
vardenafil
DrugDDI.d253.s4.e2 97 106
drug
vardenafil
DrugDDI.d253.s4.e3 134 143
drug
Vardenafil

interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e1 false
interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e2 false
interaction DrugDDI.d253.s4.e0 DrugDDI.d253.s4.e3 false
interaction DrugDDI.d253.s4.e1 DrugDDI.d253.s4.e2 false
interaction DrugDDI.d253.s4.e1 DrugDDI.d253.s4.e3 false
interaction DrugDDI.d253.s4.e2 DrugDDI.d253.s4.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s5
Erythromycin ( 500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.

DrugDDI.d253.s5.e0 0 11
drug
Erythromycin
DrugDDI.d253.s5.e1 13 15
drug
500
DrugDDI.d253.s5.e2 49 58
drug
vardenafil
DrugDDI.d253.s5.e3 109 121
drug
Vardenafil 5 mg

interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e1 false
interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e2 true
interaction DrugDDI.d253.s5.e0 DrugDDI.d253.s5.e3 false
interaction DrugDDI.d253.s5.e1 DrugDDI.d253.s5.e2 false
interaction DrugDDI.d253.s5.e1 DrugDDI.d253.s5.e3 false
interaction DrugDDI.d253.s5.e2 DrugDDI.d253.s5.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s6
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin .

DrugDDI.d253.s6.e0 42 51
drug
Vardenafil
DrugDDI.d253.s6.e1 93 104
drug
erythromycin

interaction DrugDDI.d253.s6.e0 DrugDDI.d253.s6.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s7
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.

DrugDDI.d253.s7.e0 0 11
drug
Ketoconazole
DrugDDI.d253.s7.e1 54 63
drug
vardenafil
DrugDDI.d253.s7.e2 114 123
drug
Vardenafil

interaction DrugDDI.d253.s7.e0 DrugDDI.d253.s7.e1 true
interaction DrugDDI.d253.s7.e0 DrugDDI.d253.s7.e2 false
interaction DrugDDI.d253.s7.e1 DrugDDI.d253.s7.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s8
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole .

DrugDDI.d253.s8.e0 5 14
drug
Vardenafil
DrugDDI.d253.s8.e1 77 88
drug
ketoconazole

interaction DrugDDI.d253.s8.e0 DrugDDI.d253.s8.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s9
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.

DrugDDI.d253.s9.e0 18 29
drug
ketoconazole
DrugDDI.d253.s9.e1 99 108
drug
Vardenafil
DrugDDI.d253.s9.e2 169 185
drug
ketoconazole 400 mg

interaction DrugDDI.d253.s9.e0 DrugDDI.d253.s9.e1 true
interaction DrugDDI.d253.s9.e0 DrugDDI.d253.s9.e2 false
interaction DrugDDI.d253.s9.e1 DrugDDI.d253.s9.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s10
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.

DrugDDI.d253.s10.e0 0 20
drug
HIV Protease Inhibitors
DrugDDI.d253.s10.e1 22 30
drug
Indinavir
DrugDDI.d253.s10.e2 32 34
drug
800
DrugDDI.d253.s10.e3 63 76
drug
Vardenafil 10 mg
DrugDDI.d253.s10.e4 105 114
drug
vardenafil
DrugDDI.d253.s10.e5 136 145
drug
vardenafil
DrugDDI.d253.s10.e6 170 179
drug
vardenafil

interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e1 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e2 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e3 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e0 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e2 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e3 true
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e1 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e3 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e2 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e4 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e3 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e4 DrugDDI.d253.s10.e5 false
interaction DrugDDI.d253.s10.e4 DrugDDI.d253.s10.e6 false
interaction DrugDDI.d253.s10.e5 DrugDDI.d253.s10.e6 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s11
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir .

DrugDDI.d253.s11.e0 93 101
drug
indinavir



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s12
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.

DrugDDI.d253.s12.e0 0 8
drug
Ritonavir
DrugDDI.d253.s12.e1 41 53
drug
Vardenafil 5 mg
DrugDDI.d253.s12.e2 82 91
drug
vardenafil
DrugDDI.d253.s12.e3 116 125
drug
vardenafil

interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e1 true
interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e2 false
interaction DrugDDI.d253.s12.e0 DrugDDI.d253.s12.e3 false
interaction DrugDDI.d253.s12.e1 DrugDDI.d253.s12.e2 false
interaction DrugDDI.d253.s12.e1 DrugDDI.d253.s12.e3 false
interaction DrugDDI.d253.s12.e2 DrugDDI.d253.s12.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s13
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9 .

DrugDDI.d253.s13.e0 57 66
drug
vardenafil
DrugDDI.d253.s13.e1 69 77
drug
ritonavir
DrugDDI.d253.s13.e2 92 97
drug
CYP3A4
DrugDDI.d253.s13.e3 125 130
drug
CYP2C9

interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e1 true
interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e2 false
interaction DrugDDI.d253.s13.e0 DrugDDI.d253.s13.e3 false
interaction DrugDDI.d253.s13.e1 DrugDDI.d253.s13.e2 false
interaction DrugDDI.d253.s13.e1 DrugDDI.d253.s13.e3 false
interaction DrugDDI.d253.s13.e2 DrugDDI.d253.s13.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s14
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.

DrugDDI.d253.s14.e0 0 8
drug
Ritonavir
DrugDDI.d253.s14.e1 45 54
drug
vardenafil

interaction DrugDDI.d253.s14.e0 DrugDDI.d253.s14.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s15
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir .

DrugDDI.d253.s15.e0 106 114
drug
ritonavir



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s16
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , warfarin , digoxin , Maalox , and ranitidine .

DrugDDI.d253.s16.e0 70 79
drug
vardenafil
DrugDDI.d253.s16.e1 95 99
drug
drugs
DrugDDI.d253.s16.e2 101 109
drug
glyburide
DrugDDI.d253.s16.e3 111 118
drug
warfarin
DrugDDI.d253.s16.e4 120 126
drug
digoxin
DrugDDI.d253.s16.e5 128 133
drug
Maalox
DrugDDI.d253.s16.e6 138 147
drug
ranitidine

interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e1 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e2 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e0 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e2 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e1 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e3 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e2 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e4 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e3 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e4 DrugDDI.d253.s16.e5 false
interaction DrugDDI.d253.s16.e4 DrugDDI.d253.s16.e6 false
interaction DrugDDI.d253.s16.e5 DrugDDI.d253.s16.e6 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s17
In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.

DrugDDI.d253.s17.e0 5 12
drug
warfarin
DrugDDI.d253.s17.e1 19 28
drug
vardenafil

interaction DrugDDI.d253.s17.e0 DrugDDI.d253.s17.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s18
Effects of Vardenafil on other drugs .

DrugDDI.d253.s18.e0 9 18
drug
Vardenafil
DrugDDI.d253.s18.e1 26 30
drug
drugs

interaction DrugDDI.d253.s18.e0 DrugDDI.d253.s18.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s19
In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2 , 2A6, and 2E1 ( Ki 100uM ).

DrugDDI.d253.s19.e0 15 24
drug
Vardenafil
DrugDDI.d253.s19.e1 31 41
drug
metabolites
DrugDDI.d253.s19.e2 55 60
drug
CYP1A2
DrugDDI.d253.s19.e3 73 79
drug
Ki   100uM

interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e1 false
interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e2 false
interaction DrugDDI.d253.s19.e0 DrugDDI.d253.s19.e3 false
interaction DrugDDI.d253.s19.e1 DrugDDI.d253.s19.e2 false
interaction DrugDDI.d253.s19.e1 DrugDDI.d253.s19.e3 false
interaction DrugDDI.d253.s19.e2 DrugDDI.d253.s19.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s20
Weak inhibitory effects toward other isoforms ( CYP2C8 , 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.

DrugDDI.d253.s20.e0 32 39
drug
isoforms
DrugDDI.d253.s20.e1 41 46
drug
CYP2C8

interaction DrugDDI.d253.s20.e0 DrugDDI.d253.s20.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s21
The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4 , which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.

DrugDDI.d253.s21.e0 45 54
drug
vardenafil
DrugDDI.d253.s21.e1 92 97
drug
CYP3A4
DrugDDI.d253.s21.e2 154 163
drug
Vardenafil

interaction DrugDDI.d253.s21.e0 DrugDDI.d253.s21.e1 false
interaction DrugDDI.d253.s21.e0 DrugDDI.d253.s21.e2 false
interaction DrugDDI.d253.s21.e1 DrugDDI.d253.s21.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s22
In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.

DrugDDI.d253.s22.e0 14 21
drug
Nitrates
DrugDDI.d253.s22.e1 66 73
drug
nitrates
DrugDDI.d253.s22.e2 101 110
drug
vardenafil
DrugDDI.d253.s22.e3 185 194
drug
Vardenafil

interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e1 false
interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e2 false
interaction DrugDDI.d253.s22.e0 DrugDDI.d253.s22.e3 false
interaction DrugDDI.d253.s22.e1 DrugDDI.d253.s22.e2 false
interaction DrugDDI.d253.s22.e1 DrugDDI.d253.s22.e3 false
interaction DrugDDI.d253.s22.e2 DrugDDI.d253.s22.e3 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s23
These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.

DrugDDI.d253.s23.e0 31 44
drug
Vardenafil 20 mg



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s24
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.

DrugDDI.d253.s24.e0 37 44
drug
nitrates
DrugDDI.d253.s24.new.DISO.e3 60 79
DISO
ischemic heart disease
DrugDDI.d253.s24.e1 119 128
drug
Vardenafil
DrugDDI.d253.s24.e2 132 139
drug
nitrates

interaction DrugDDI.d253.s24.e0 DrugDDI.d253.s24.e1 false
interaction DrugDDI.d253.s24.e0 DrugDDI.d253.s24.e2 false
interaction DrugDDI.d253.s24.e1 DrugDDI.d253.s24.e2 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s25
Nifedipine : Vardenafil 20 mg , when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4 .

DrugDDI.d253.s25.e0 0 9
drug
Nifedipine
DrugDDI.d253.s25.e1 11 24
drug
Vardenafil 20 mg
DrugDDI.d253.s25.e2 61 74
drug
nifedipine 30 mg
DrugDDI.d253.s25.e3 164 173
drug
nifedipine
DrugDDI.d253.s25.e4 176 179
drug
drug
DrugDDI.d253.s25.e5 200 205
drug
CYP3A4

interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e1 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e2 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e0 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e2 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e1 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e3 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e2 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e3 DrugDDI.d253.s25.e4 false
interaction DrugDDI.d253.s25.e3 DrugDDI.d253.s25.e5 false
interaction DrugDDI.d253.s25.e4 DrugDDI.d253.s25.e5 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s26
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.

DrugDDI.d253.s26.e0 0 9
drug
Nifedipine
DrugDDI.d253.s26.e1 38 47
drug
Vardenafil

interaction DrugDDI.d253.s26.e0 DrugDDI.d253.s26.e1 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s27
In these patients whose hypertension was controlled with nifedipine , Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.

DrugDDI.d253.s27.e0 49 58
drug
nifedipine
DrugDDI.d253.s27.e1 60 73
drug
Vardenafil 20 mg

interaction DrugDDI.d253.s27.e0 DrugDDI.d253.s27.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s28
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin , significant hypotension developed in a substantial number of subjects.

DrugDDI.d253.s28.e0 19 28
drug
Vardenafil
DrugDDI.d253.s28.e1 108 116
drug
terazosin

interaction DrugDDI.d253.s28.e0 DrugDDI.d253.s28.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s29
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

DrugDDI.d253.s29.e0 24 37
drug
Vardenafil 10 mg
DrugDDI.d253.s29.e1 41 51
drug
terazosin 10

interaction DrugDDI.d253.s29.e0 DrugDDI.d253.s29.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s30
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

DrugDDI.d253.s30.e0 24 37
drug
Vardenafil 20 mg
DrugDDI.d253.s30.e1 41 51
drug
terazosin 10

interaction DrugDDI.d253.s30.e0 DrugDDI.d253.s30.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s31
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s31.e0 4 13
drug
Vardenafil
DrugDDI.d253.s31.e1 36 46
drug
terazosin 10
DrugDDI.d253.s31.e2 88 97
drug
Vardenafil

interaction DrugDDI.d253.s31.e0 DrugDDI.d253.s31.e1 false
interaction DrugDDI.d253.s31.e0 DrugDDI.d253.s31.e2 false
interaction DrugDDI.d253.s31.e1 DrugDDI.d253.s31.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s32
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s32.e0 19 28
drug
tamsulosin
DrugDDI.d253.s32.e1 71 84
drug
Vardenafil 20 mg
DrugDDI.d253.s32.e2 88 102
drug
tamsulosin 0.4 mg

interaction DrugDDI.d253.s32.e0 DrugDDI.d253.s32.e1 false
interaction DrugDDI.d253.s32.e0 DrugDDI.d253.s32.e2 false
interaction DrugDDI.d253.s32.e1 DrugDDI.d253.s32.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s33
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.

DrugDDI.d253.s33.e0 38 51
drug
Vardenafil 10 mg
DrugDDI.d253.s33.e1 55 69
drug
tamsulosin 0.4 mg

interaction DrugDDI.d253.s33.e0 DrugDDI.d253.s33.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s34
The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.

DrugDDI.d253.s34.e0 31 40
drug
Vardenafil



Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s35
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.

DrugDDI.d253.s35.e0 17 26
drug
Vardenafil
DrugDDI.d253.s35.e1 54 66
drug
alpha-blocker

interaction DrugDDI.d253.s35.e0 DrugDDI.d253.s35.e1 true

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s36
Ritonavir and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%.

DrugDDI.d253.s36.e0 0 8
drug
Ritonavir
DrugDDI.d253.s36.e1 12 20
drug
indinavir
DrugDDI.d253.s36.e2 58 67
drug
Vardenafil
DrugDDI.d253.s36.e3 80 88
drug
ritonavir
DrugDDI.d253.s36.e4 105 113
drug
ritonavir

interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e1 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e2 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e3 false
interaction DrugDDI.d253.s36.e0 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e2 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e3 false
interaction DrugDDI.d253.s36.e1 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e2 DrugDDI.d253.s36.e3 true
interaction DrugDDI.d253.s36.e2 DrugDDI.d253.s36.e4 false
interaction DrugDDI.d253.s36.e3 DrugDDI.d253.s36.e4 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s37
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.

DrugDDI.d253.s37.e0 26 35
drug
Vardenafil
DrugDDI.d253.s37.e1 48 56
drug
indinavir
DrugDDI.d253.s37.e2 73 81
drug
indinavir

interaction DrugDDI.d253.s37.e0 DrugDDI.d253.s37.e1 true
interaction DrugDDI.d253.s37.e0 DrugDDI.d253.s37.e2 false
interaction DrugDDI.d253.s37.e1 DrugDDI.d253.s37.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s38
Alcohol : Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.

DrugDDI.d253.s38.e0 0 6
drug
Alcohol
DrugDDI.d253.s38.e1 8 14
drug
Alcohol
DrugDDI.d253.s38.e2 85 94
drug
vardenafil

interaction DrugDDI.d253.s38.e0 DrugDDI.d253.s38.e1 false
interaction DrugDDI.d253.s38.e0 DrugDDI.d253.s38.e2 false
interaction DrugDDI.d253.s38.e1 DrugDDI.d253.s38.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s39
Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).

DrugDDI.d253.s39.e0 0 9
drug
Vardenafil
DrugDDI.d253.s39.e1 55 61
drug
alcohol
DrugDDI.d253.s39.e2 133 139
drug
alcohol

interaction DrugDDI.d253.s39.e0 DrugDDI.d253.s39.e1 false
interaction DrugDDI.d253.s39.e0 DrugDDI.d253.s39.e2 false
interaction DrugDDI.d253.s39.e1 DrugDDI.d253.s39.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s40
Aspirin : Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).

DrugDDI.d253.s40.e0 0 6
drug
Aspirin
DrugDDI.d253.s40.e1 8 17
drug
Vardenafil
DrugDDI.d253.s40.e2 80 86
drug
aspirin

interaction DrugDDI.d253.s40.e0 DrugDDI.d253.s40.e1 false
interaction DrugDDI.d253.s40.e0 DrugDDI.d253.s40.e2 false
interaction DrugDDI.d253.s40.e1 DrugDDI.d253.s40.e2 false

Abstract Id: DrugDDI.d253
Sentence Id: DrugDDI.d253.s41
Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide ( glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).

DrugDDI.d253.s41.e0 18 27
drug
Vardenafil
DrugDDI.d253.s41.e1 62 70
drug
glyburide
DrugDDI.d253.s41.e2 72 78
drug
glucose
DrugDDI.d253.s41.e3 82 88
drug
insulin
DrugDDI.d253.s41.e4 107 114
drug
warfarin

interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e1 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e2 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e0 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e2 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e1 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e2 DrugDDI.d253.s41.e3 false
interaction DrugDDI.d253.s41.e2 DrugDDI.d253.s41.e4 false
interaction DrugDDI.d253.s41.e3 DrugDDI.d253.s41.e4 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s0
Zidovudine : There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.

DrugDDI.d528.s0.e0 0 9
drug
Zidovudine
DrugDDI.d528.s0.e1 64 66
drug
ZDV
DrugDDI.d528.s0.e2 70 80
drug
zalcitabine

interaction DrugDDI.d528.s0.e0 DrugDDI.d528.s0.e1 false
interaction DrugDDI.d528.s0.e0 DrugDDI.d528.s0.e2 false
interaction DrugDDI.d528.s0.e1 DrugDDI.d528.s0.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s1
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).

DrugDDI.d528.s1.e0 0 10
drug
Zalcitabine
DrugDDI.d528.s1.e1 72 74
drug
ZDV

interaction DrugDDI.d528.s1.e0 DrugDDI.d528.s1.e1 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s2
In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.

DrugDDI.d528.s2.e0 28 37
drug
didanosine
DrugDDI.d528.s2.e1 41 49
drug
stavudine
DrugDDI.d528.s2.e2 107 117
drug
zalcitabine

interaction DrugDDI.d528.s2.e0 DrugDDI.d528.s2.e1 false
interaction DrugDDI.d528.s2.e0 DrugDDI.d528.s2.e2 false
interaction DrugDDI.d528.s2.e1 DrugDDI.d528.s2.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s3
Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.

DrugDDI.d528.s3.e0 0 9
drug
Lamivudine
DrugDDI.d528.s3.e1 89 98
drug
lamivudine
DrugDDI.d528.s3.e2 121 131
drug
zalcitabine

interaction DrugDDI.d528.s3.e0 DrugDDI.d528.s3.e1 false
interaction DrugDDI.d528.s3.e0 DrugDDI.d528.s3.e2 false
interaction DrugDDI.d528.s3.e1 DrugDDI.d528.s3.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s4
Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.

DrugDDI.d528.s4.e0 111 121
drug
zalcitabine
DrugDDI.d528.s4.e1 132 142
drug
metabolites
DrugDDI.d528.s4.e2 162 172
drug
zalcitabine

interaction DrugDDI.d528.s4.e0 DrugDDI.d528.s4.e1 false
interaction DrugDDI.d528.s4.e0 DrugDDI.d528.s4.e2 false
interaction DrugDDI.d528.s4.e1 DrugDDI.d528.s4.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s5
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100); .

DrugDDI.d528.s5.e0 0 10
drug
Zalcitabine
DrugDDI.d528.s5.e1 20 29
drug
lamivudine

interaction DrugDDI.d528.s5.e0 DrugDDI.d528.s5.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s6
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine .

DrugDDI.d528.s6.e0 66 75
drug
lamivudine
DrugDDI.d528.s6.e1 116 125
drug
lamivudine
DrugDDI.d528.s6.e2 154 172
drug
deoxycytidine kinase
DrugDDI.d528.s6.e3 177 187
drug
zalcitabine

interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e1 false
interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e2 false
interaction DrugDDI.d528.s6.e0 DrugDDI.d528.s6.e3 false
interaction DrugDDI.d528.s6.e1 DrugDDI.d528.s6.e2 false
interaction DrugDDI.d528.s6.e1 DrugDDI.d528.s6.e3 false
interaction DrugDDI.d528.s6.e2 DrugDDI.d528.s6.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s7
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine .

DrugDDI.d528.s7.e0 57 67
drug
zalcitabine
DrugDDI.d528.s7.e1 71 80
drug
lamivudine
DrugDDI.d528.s7.e2 151 161
drug
zalcitabine
DrugDDI.d528.s7.e3 209 219
drug
zalcitabine

interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e1 true
interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e2 false
interaction DrugDDI.d528.s7.e0 DrugDDI.d528.s7.e3 false
interaction DrugDDI.d528.s7.e1 DrugDDI.d528.s7.e2 false
interaction DrugDDI.d528.s7.e1 DrugDDI.d528.s7.e3 false
interaction DrugDDI.d528.s7.e2 DrugDDI.d528.s7.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s9
Concomitant use of zalcitabine and lamivudine is not recommended.

DrugDDI.d528.s9.e0 16 26
drug
zalcitabine
DrugDDI.d528.s9.e1 30 39
drug
lamivudine

interaction DrugDDI.d528.s9.e0 DrugDDI.d528.s9.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s10
Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults.

DrugDDI.d528.s10.e0 0 9
drug
Saquinavir
DrugDDI.d528.s10.e1 27 31
drug
HIVID
DrugDDI.d528.s10.e2 33 42
drug
saquinavir
DrugDDI.d528.s10.e3 47 49
drug
ZDV

interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e1 false
interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e2 false
interaction DrugDDI.d528.s10.e0 DrugDDI.d528.s10.e3 false
interaction DrugDDI.d528.s10.e1 DrugDDI.d528.s10.e2 false
interaction DrugDDI.d528.s10.e1 DrugDDI.d528.s10.e3 false
interaction DrugDDI.d528.s10.e2 DrugDDI.d528.s10.e3 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s11
Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.

DrugDDI.d528.s11.e0 79 83
drug
drugs



Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s12
Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.

DrugDDI.d528.s12.e0 0 4
drug
Drugs
DrugDDI.d528.s12.new.DISO.e3 19 38
DISO
Peripheral Neuropathy
DrugDDI.d528.s12.e1 59 63
drug
HIVID
DrugDDI.d528.s12.e2 68 72
drug
drugs
DrugDDI.d528.s12.new.DISO.e4 110 119
DISO
neuropathy

interaction DrugDDI.d528.s12.e0 DrugDDI.d528.s12.e1 false
interaction DrugDDI.d528.s12.e0 DrugDDI.d528.s12.e2 false
interaction DrugDDI.d528.s12.e1 DrugDDI.d528.s12.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s13
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .

DrugDDI.d528.s13.e0 0 4
drug
Drugs
DrugDDI.d528.s13.new.DISO.e17 31 50
DISO
peripheral neuropathy
DrugDDI.d528.s13.e1 58 90
drug
antiretroviral nucleoside analogues
DrugDDI.d528.s13.e2 92 106
drug
chloramphenicol
DrugDDI.d528.s13.e3 108 116
drug
cisplatin
DrugDDI.d528.s13.e4 118 124
drug
dapsone
DrugDDI.d528.s13.e5 126 135
drug
disulfiram
DrugDDI.d528.s13.e6 137 147
drug
ethionamide
DrugDDI.d528.s13.e7 149 160
drug
glutethimide
DrugDDI.d528.s13.e8 162 165
drug
gold
DrugDDI.d528.s13.e9 167 177
drug
hydralazine
DrugDDI.d528.s13.e10 179 188
drug
iodoquinol
DrugDDI.d528.s13.e11 190 198
drug
isoniazid
DrugDDI.d528.s13.e12 200 212
drug
metronidazole
DrugDDI.d528.s13.e13 214 227
drug
nitrofurantoin
DrugDDI.d528.s13.e14 229 237
drug
phenytoin
DrugDDI.d528.s13.e15 239 247
drug
ribavirin
DrugDDI.d528.s13.e16 252 262
drug
vincristine

interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e1 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e2 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e0 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e2 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e1 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e3 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e2 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e4 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e3 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e5 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e4 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e6 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e5 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e7 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e6 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e8 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e7 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e9 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e8 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e10 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e9 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e11 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e10 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e12 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e11 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e13 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e12 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e14 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e13 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e14 DrugDDI.d528.s13.e15 false
interaction DrugDDI.d528.s13.e14 DrugDDI.d528.s13.e16 false
interaction DrugDDI.d528.s13.e15 DrugDDI.d528.s13.e16 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s14
Concomitant use of HIVID with didanosine is not recommended.

DrugDDI.d528.s14.e0 16 20
drug
HIVID
DrugDDI.d528.s14.e1 25 34
drug
didanosine

interaction DrugDDI.d528.s14.e0 DrugDDI.d528.s14.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s15
Intravenous Pentamidin e: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.

DrugDDI.d528.s15.e0 11 20
drug
Pentamidin
DrugDDI.d528.s15.e1 36 40
drug
HIVID
DrugDDI.d528.s15.e2 73 76
drug
drug
DrugDDI.d528.s15.new.DISO.e3 103 114
DISO
pancreatitis

interaction DrugDDI.d528.s15.e0 DrugDDI.d528.s15.e1 false
interaction DrugDDI.d528.s15.e0 DrugDDI.d528.s15.e2 false
interaction DrugDDI.d528.s15.e1 DrugDDI.d528.s15.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s16
Death due to fulminant pancreatitis possibly related to intravenous pentamidin e and HIVID has been reported.

DrugDDI.d528.s16.new.DISO.e2 19 30
DISO
pancreatitis
DrugDDI.d528.s16.e0 59 68
drug
pentamidin
DrugDDI.d528.s16.e1 73 77
drug
HIVID

interaction DrugDDI.d528.s16.e0 DrugDDI.d528.s16.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s17
If intravenous pentamidin e is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.

DrugDDI.d528.s17.e0 13 22
drug
pentamidin
DrugDDI.d528.s17.new.DISO.e2 41 68
DISO
Pneumocystis carinii pneumonia
DrugDDI.d528.s17.e1 83 87
drug
HIVID

interaction DrugDDI.d528.s17.e0 DrugDDI.d528.s17.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s18
Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).

DrugDDI.d528.s18.e0 0 11
drug
Amphotericin
DrugDDI.d528.s18.e1 13 21
drug
Foscarnet
DrugDDI.d528.s18.e2 26 40
drug
Aminoglycosides
DrugDDI.d528.s18.e3 42 46
drug
Drugs
DrugDDI.d528.s18.e4 53 64
drug
amphotericin
DrugDDI.d528.s18.e5 66 74
drug
foscarnet
DrugDDI.d528.s18.e6 79 93
drug
aminoglycosides
DrugDDI.d528.s18.new.DISO.e9 124 143
DISO
peripheral neuropathy
DrugDDI.d528.s18.e7 151 155
drug
HIVID
DrugDDI.d528.s18.e8 216 226
drug
zalcitabine

interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e1 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e2 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e0 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e2 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e1 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e3 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e2 DrugDDI.d528.s18.e8 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e4 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e3 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e5 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e4 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e6 false
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e5 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e6 DrugDDI.d528.s18.e7 false
interaction DrugDDI.d528.s18.e6 DrugDDI.d528.s18.e8 true
interaction DrugDDI.d528.s18.e7 DrugDDI.d528.s18.e8 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s19
Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.

DrugDDI.d528.s19.e0 36 40
drug
drugs
DrugDDI.d528.s19.e1 45 49
drug
HIVID

interaction DrugDDI.d528.s19.e0 DrugDDI.d528.s19.e1 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s20
Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine .

DrugDDI.d528.s20.e0 0 9
drug
Probenecid
DrugDDI.d528.s20.e1 12 21
drug
Cimetidine
DrugDDI.d528.s20.e2 50 59
drug
probenecid
DrugDDI.d528.s20.e3 62 71
drug
cimetidine
DrugDDI.d528.s20.e4 97 107
drug
zalcitabine
DrugDDI.d528.s20.e5 156 166
drug
zalcitabine

interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e1 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e2 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e4 false
interaction DrugDDI.d528.s20.e0 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e2 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e4 false
interaction DrugDDI.d528.s20.e1 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e3 false
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e4 true
interaction DrugDDI.d528.s20.e2 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e3 DrugDDI.d528.s20.e4 true
interaction DrugDDI.d528.s20.e3 DrugDDI.d528.s20.e5 false
interaction DrugDDI.d528.s20.e4 DrugDDI.d528.s20.e5 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s21
Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.

DrugDDI.d528.s21.e0 22 26
drug
drugs
DrugDDI.d528.s21.e1 44 54
drug
zalcitabine
DrugDDI.d528.s21.e2 102 112
drug
zalcitabine

interaction DrugDDI.d528.s21.e0 DrugDDI.d528.s21.e1 true
interaction DrugDDI.d528.s21.e0 DrugDDI.d528.s21.e2 false
interaction DrugDDI.d528.s21.e1 DrugDDI.d528.s21.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s22
Magnesium /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium /aluminum-containing antacid products.

DrugDDI.d528.s22.e0 0 8
drug
Magnesium
DrugDDI.d528.s22.e1 9 35
drug
/Aluminum-containing Antacid
DrugDDI.d528.s22.e2 57 67
drug
zalcitabine
DrugDDI.d528.s22.e3 127 135
drug
magnesium
DrugDDI.d528.s22.e4 136 162
drug
/aluminum-containing antacid

interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e1 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e2 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e3 false
interaction DrugDDI.d528.s22.e0 DrugDDI.d528.s22.e4 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e2 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e3 false
interaction DrugDDI.d528.s22.e1 DrugDDI.d528.s22.e4 false
interaction DrugDDI.d528.s22.e2 DrugDDI.d528.s22.e3 true
interaction DrugDDI.d528.s22.e2 DrugDDI.d528.s22.e4 true
interaction DrugDDI.d528.s22.e3 DrugDDI.d528.s22.e4 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s23
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum-containing antacids .

DrugDDI.d528.s23.e0 54 64
drug
zalcitabine
DrugDDI.d528.s23.e1 111 119
drug
magnesium
DrugDDI.d528.s23.e2 121 147
drug
aluminum-containing antacids

interaction DrugDDI.d528.s23.e0 DrugDDI.d528.s23.e1 true
interaction DrugDDI.d528.s23.e0 DrugDDI.d528.s23.e2 true
interaction DrugDDI.d528.s23.e1 DrugDDI.d528.s23.e2 false

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s24
Metoclopramide : Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.

DrugDDI.d528.s24.e0 0 13
drug
Metoclopramide
DrugDDI.d528.s24.e1 67 77
drug
zalcitabine
DrugDDI.d528.s24.e2 81 94
drug
metoclopramide

interaction DrugDDI.d528.s24.e0 DrugDDI.d528.s24.e1 false
interaction DrugDDI.d528.s24.e0 DrugDDI.d528.s24.e2 false
interaction DrugDDI.d528.s24.e1 DrugDDI.d528.s24.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s25
Doxorubicin : Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.

DrugDDI.d528.s25.e0 0 10
drug
Doxorubicin
DrugDDI.d528.s25.e1 12 22
drug
Doxorubicin
DrugDDI.d528.s25.e2 40 50
drug
zalcitabine

interaction DrugDDI.d528.s25.e0 DrugDDI.d528.s25.e1 false
interaction DrugDDI.d528.s25.e0 DrugDDI.d528.s25.e2 false
interaction DrugDDI.d528.s25.e1 DrugDDI.d528.s25.e2 true

Abstract Id: DrugDDI.d528
Sentence Id: DrugDDI.d528.s26
Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.

DrugDDI.d528.s26.e0 27 37
drug
zalcitabine
DrugDDI.d528.s26.e1 63 78
drug
active metabolite

interaction DrugDDI.d528.s26.e0 DrugDDI.d528.s26.e1 false

